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SUMMARY 
 
  
Summary 
 
Cystic fibrosis (CF) is caused due to the dysregulation of cystic fibrosis 
ransmembrane conductance regulator (CFTR) and epithelial sodium channel 
(ENaC). CFTR is a negative regulator of the amiloride-sensitive ENaC that 
constitutes the limiting pathway for sodium (Na+) and fluid absorption. Mutation in 
CFTR gene leads to ENaC channel overexpression and results in Na+ hyper-
absorption in airways. Defective CFTR leads to enhanced mucus viscosity, 
decreased muco-ciliary clearance and bacterial colonization. It is assumed that 
impaired toll-like receptor-4 (TLR-4) mediated innate and adaptive immune 
responses affect chronic bacterial infection of CF airways. The reduced TLR-4 
surface expression might be associated with increased iron concentration and 
hypoxia via downregulation of hemeoxygenase-1 in CF airways.  
 
Iron transport in the epithelium is associated with transcellular movement of 
Na+/K+-ATPase and ENaC. We speculate that increased intracellular iron might 
be a result of ENaC mediated high Na+ and subsequent iron bypass in CF 
airways. Alterations in iron homeostasis have been previously studied in CF. 
However, expression of ferroportin, which is the only known iron exporter, has 
not been well studied in CF epithelial cells. 
 
Recent studies suggest that microRNA-16 (miR-16) and transforming growth 
factor-β (TGF-β) regulate the ENaC channel in acute lung injury (ALI) and are 
nvolved in CFTR regulation in CF. We hypothesized that miR-16 and TGF-β 
might have a role in modulating ENaC channels and regulate the ferroportin and 
TLR-4 expression in CF epithelial cells. Therefore, we investigated in vitro roles 
of miR-16 on TGF-β expression in CF. Further, we studied in vitro effects of 
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exogenous TGF-β mediated direct inhibition of ENaC, ferroportin and subsequent 
TLR-4 expression in CF.  
Cystic fibrosis bronchial epithelial cell line (CFBE41o-) and normal human 
bronchial epithelial cell lines (16HBE14o-) were used for in vitro analysis for 
protein and mRNA expression via immunoblotting, qPCR, immunofluorescence, 
enzyme-linked immunosorbent assay and transfection. Immunohistochemistry 
analysis of TGF-β was performed on lung sections from CF patients and donor.  
 
We observed reduced TGF-β and ferroportin expression in CFBE41o- cells as 
compared to 16HBE14o- cell lines. Additionally, hypoxic condition showed up-
regulation of the TGF-β and ferroportin expression, suggesting a role of hypoxia 
in downregulation of TGF-β and ferroportin expression in CF cells. Exogenous 
application of TGF-β revealed the increase of ferroportin and TLR-4 surface 
expression. Direct inhibition of ENaC by EIPA also resulted in increased 
ferroportin and TLR-4 expression in CFBE41o- cells. Immunofluorescence 
studies confirmed the increase of ferroportin and TLR-4 surface expression upon 
TGF-β and EIPA treatments. 
 
To conclude, our in vitro results demonstrate that miR-16 and hypoxia might be 
responsible for reduced TGF-β and ferroportin expression in CFBE41o- cells. 
Further exogenous supplement of TGF-β and direct inhibition of ENaC by EIPA 
was correlated with increased ferroportin expression and improve TLR-4 surface 
expression in CFBE41o- cells.  
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Zusammenfassung 
 
Zystische Fibrose (CF) wird durch eine Dysregulation des Cystic Fibrosis 
Transmembrane Conductance Regulator Kanals (CFTR) und des epithelialen 
Na+ Kanals (Epithelial Sodium Channel, ENaC) verursacht. CFTR wirkt als ein 
negativer Regulator für den amiloride-sensitiven epithelialen Na+ Kanal (ENaC), 
dies ist was die limitierende Signalkaskade für Na+ und der 
Flüssigkeitsabsorption bildet. Mutationen in CFTR-Genen führen zu einer 
Überexpression von ENaC-Kanälen und resultiert in eine Na+ Hyperabsorption in 
den Atemwegen. Dies führt zu einer erhöhten Schleimviskosität, veringerter 
Mukoziliärer-Clearance und Bakterienkolonisation. Es wird angenommen, dass 
eine chronische Bakterienbesiedelung der CF Atemwege durch Toll Like 
Rezeptor-4 (TLR-4) vermittelte Immunantwort beeinflusst wird. Wir konnten 
feststellen, dass TLR-4 bei CF verringert an der Oberfläche exprimiert wird. Dies 
könnte mit einer erhöhten Eisenkonzentration und beeinträchtigter Hypoxie durch 
Runterregulation von Hämoxygenase-1 in CF Atemwegen assoziiert sein. 
Der epitheliale Eisentransport ist mit einer transzellulären Bewegung der Na+/K+-
ATPase und dem epithelialen Na+ Kanal assoziiert. Wir vermuten, dass erhöhtes 
intrazelluläres Eisen, durch den ENaC-Kanal vermittelten hohen Na+ Gehalt mit 
anschließender Eisenumleitung in CF Atemwege, assoziiert ist. Veränderungen 
in der Eisenhomöostase wurden bereits früher bei CF vermutet. Jedoch, die 
Expression von Ferroportin, der einzig bekannte Eisenexporter, wurde in CF 
epithelialen Zellen noch nicht untersucht. 
Aktuelle Untersuchungen deuten darauf hin, dass microRNA-16 (miR-16) und 
transforming growth factor-β (TGF-β) bei akutem Lungenversagen (ALI) die 
ENaC Kanäle regulieren und auch in der CFTR-Regulierung bei CF beteiligt sind. 
Wir vermuten, dass miR-16 und TGF-β eventuell eine Rolle in der Modulation der 
ENaC Kanäle und der Regulation von Ferroportin und TLR-4 Expression in der 
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CF Epithelzelle hat. Daher haben wir in vitro die Role von miR-16 on TGF-β bei 
CF Epithelzellen untersucht. Des Weiteren untersuchten wir den in vitro Effekt 
von exogener TGF-β vermittelter direkter Inhibition von ENaC, Ferroportin und 
der folgender TLR-4 Expression bei CF. 
Zystische Fibrose bronchiale Epithelzelllinien (CFBE41o-) und normale humane 
bronchiale Epithelzelllinien (16HBE14o-) wurden für in vitro Analysen von 
Proteinen und mRNA Expression via Immunoblotting, qPCR, 
Immunofluorescence, enzyme-linked immunosorbent assay und Transfektion 
verwendet. Immunohistochemie Analysen von TGF-β wurden an 
Lungenschnitten von CF-Patienten und Kontrolllungenschnitten ausgeführt. 
Wir sahen eine verringerte TGF-β und Ferroportin Expression in CFBE41o- 
Zellen im Vergleich zu 16HBE14o- Zellen. Zusätzlich bestand unter hypoxischen 
Bedingungen eine Hochregulation der TGF-β und Ferroportin Expression, was 
andeutet, dass veränderter Hypoxie, in runterregulierter TGF-β und Ferroportin 
Expression in CF Zellen, eine Rolle spielt. Exogene Zufuhr von TGF-β zeigte 
einen Anstieg von Ferroportin und TLR-4 Oberflächenexpression. Direkte 
Inhibition von ENaC durch EIPA resultierte in eine erhöhte Ferroportin und TLR-4 
Expression in CFBE41o- Zellen. Immunofluoreszens Experimente bestätigten 
den Anstieg von Ferroportin und TLR-4 Oberflächenexpression durch TGF-β und 
EIPA Behandlung. 
Zusammenfassend, zeigen unsere in vitro Ergebnisse, dass miR-16 und Hypoxie 
eventuell für eine verringerte TGF-β und Ferroportin Expression in CFBE41o- 
Zellen verantwortlich sind. Des Weiteren, dass Zusatz von TGF-β und direkte 
Inhibition von ENaC durch EIPA mit erhöhter Ferroportin Expression und 
verbesserter TLR-4 Oberflächenexpression in CFBE41o- Zellen korrelieren. 
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1 Introduction 
1.1 Cystic fibrosis 
 
Cystic fibrosis (CF) is a life-limiting inherited disorder that affects ~70,000 
individuals worldwide. CF mostly affects the Caucasians; however, it has been 
reported in all races and ethnicities. It is an autosomal recessive disease caused 
by one or more mutations in the gene encoding cystic fibrosis transmembrane 
conductance regulator (CFTR) [1-3]. Mutation in CFTR gene leads to CFTR 
protein dysfunctions. This condition is autosomal recessive which means both 
copies of the gene are mutated in each cell [4]. Individuals whose parent carries 
one functional copy of mutated CFTR gene do not exhibit any signs and 
symptoms of cystic fibrosis. One copy of the gene can also exhibit the complete 
function of CFTR protein [5]. CFTR not only functions in regulation of apical 
epithelial chloride channel but also regulates other channels such as epithelial 
Na+ channel (ENaC) [6], Ca2+ -activated chloride conductance (CaCC), renal 
outer medullary K+ (ROMK) channel, sodium/proton exchanger 3 (NHE3), and 
aquaporin channel [7]. 
 
Currently, there are nearly 2,000 mutations noted in CFTR gene [8]. Depending 
upon the abnormalities in this gene, these mutations are divided into 5 types 
ranging from complete loss of protein synthesis to normal apical membrane 
expression of the protein with poor chloride conductance [7]. The most common 
mutation is the deletion of phenylalanine at 508th position (ΔF508del mutation) of 
the gene. In this mutation, CFTR gene is synthesized in an immature form that 
leads to improper folding of CFTR protein in the endoplasmic reticulum (ER) and 
further degraded by ER-chaperons. It causes reduction of its function and affects 
the chloride transport at the apical plasma membrane [9].  
 
In healthy airways, CFTR acts as cyclic adenosine 3',5'-monophosphate (cAMP)-
regulated chloride channels [10]. Thus, defective CFTR impairs chloride-ion 
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transport across epithelial surfaces and mucosal membranes [9]. Organs 
containing epithelia such as lungs, pancreas, gastrointestinal system, 
hepatobiliary system, reproductive system, and sweat glands are all severely 
affected in CF disease. Among these, the pulmonary airways display distinct 
changes with a basic genetic defect, which results in the significantly reduced life 
expectancy of CF patients [11, 12]. 
 
Defective CFTR causes alteration of epithelial salt and water transport within the 
cells and excessive sodium reabsorption lead to dehydrated airway surface fluid 
and impaired muco-ciliary clearance (Figure-1). Further, it results into abnormal 
viscous mucus secretions in the lung airways thereby causing difficulty in 
breathing and declination of lung functions. 
 
    
 
 
Figure 1: Cystic fibrosis epithelium [13] 
 
Thickened mucus secretion provides a suitable environment for bacterial growth. 
Over the time of CF progression, CF patients are infected with various pathogens 
such as Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus (S. 
aureus) and Burkholderia cenocepacia (B. cenocepacia).  
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Chronic infection with P. aeruginosa is known as a major perpetrator in CF, that 
leads to epithelial surface damage and airway blocking, which further impairs the 
airway conductance [14]. These result in decline of pulmonary functions and 
contribute to over 85-90% of deaths in CF patients [15]. An exaggerated 
inflammatory response due to chronic bacterial infection is one of the contributing 
factors in worsening of CF [16]. Several studies have suggested that defective 
CFTR may directly affect airway immunity with exaggerated production of pro-
inflammatory mediators and impaired immune responses to pathogens [17]. 
 
1.2 Innate immunity 
Clinical data suggest that CF initiates due to altered host defense system of the 
airways and failure to clear the bacterial infection. This leads to chronic 
inflammation and contributes to obstructive lung diseases eventually associated 
with the respiratory failure [18]. The innate immune system is the first line of 
defense against pathogens, which additionally signals to acquire immune system 
for activation of T and B cells to specific antigens. The innate immune system not 
only provides barriers to colonization and infection but also determines antigen 
specificity and the nature of the response to be carried out by acquired immunity 
[19]. Innate immunity prevents bacterial infections by rapid recruitment of 
phagocytic cells, effective signal transduction systems, muco-ciliary escalator, 
proteases, anti-proteases, antimicrobials, immediate production of reactive 
oxygen species (ROS), and pattern recognition receptors (PPRs) [20].  
 
The response of innate immunity in the detection of pathogens relies on the 
recognition of various pathogen-associated molecular patterns (PAMPs), which 
include complex lipids, lipopolysaccharides, carbohydrates, unmethylated 
cytosine-guanosine, DNA sequences, and double-stranded RNAs [21]. PAMPs 
are recognized by the host’s pattern recognition receptors (PRRs). Upon 
recognition, it signals to the host about the presence of infections and initiates 
immune responses by activation of the intracellular cascade to trigger pro-
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inflammatory and antimicrobial agents to clear the infections [22].  
 
PPR mediated signaling ultimately leads to the activation of gene expression and 
synthesis of various cytokines, chemokines, cell adhesion molecules, and 
immune receptors [21], which together play roles in early host response to 
infections and initiate the link for adaptive immune responses. This, in turn, 
promotes the repair of damaged tissues, and assist in the restoration of tissue 
functions. The basic underlying mechanisms for innate immune recognition are 
highly conserved among all species. 
 
The key components of the innate immunity include epithelial cells, neutrophils, 
and alveolar macrophages. These cells not only function in clearing pathogens 
but also co-ordinate the immune responses against the infections. Airway 
secretions, which contain anti-microbial peptides and proteins directly acts on 
pathogens and modulate the inflammatory responses [18]. Defective CFTR leads 
to impairment of epithelial cell functions such as bacterial killing, transport of 
glutathione (GSH) and cytokine production. Also, there is deterioration of 
neutrophil functions such as phagocytosis, degranulation, apoptosis, anti-
microbial activity, cytokine production and TLR-2, 4, 5 expressions. Furthermore, 
macrophage functions such as clearance of apoptotic cells, cytokine production, 
phagocytosis acidification of lysosomes and antigen presentation are affected. 
 
In CF patients, mutation in CFTR causes critical impairment of innate host 
immune responses. Mechanisms of how faulty CFTR result in impaired immune 
responses is not fully understood. This compromised immune response results in 
an early and severe form of chronic airways disorders, featuring thick mucus 
obstruction with chronic bacterial infections, neutrophil-dominated airway 
inflammation, finally leading to progressive pulmonary damage with 
bronchiectasis and emphysema [23].  
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1.3 Toll-like receptors (TLRs) 
 
TLRs are the first line of defense key sensors in innate immune response and 
constitute a highly conserved family of pattern recognition receptors. These are 
expressed by epithelial and immune cells, which allow the host to detect the 
presence of microbial infections. TLRs mediate response by sensing pathogen-
associated molecular patterns (PAMPs), and danger-associated molecular 
patterns (DAMPs). 
 
Upon detection of these conserved molecular patterns in microbial factors and 
endogenous danger signals, TLRs provide rapid stimulation of intracellular 
signaling cascades of innate immunity for the expression of various inflammatory 
mediators including tumor necrosis factor alpha (TNF-α), nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) and interleukin-8 to coordinate 
the early host response to infection. Thirteen TLRs have been identified up to 
date and their respective ligands are as follows: 
 
Table 1- Toll like receptors and their ligands [22, 24, 25] 
Receptors Ligands 
TLR-1 Bacterial lipopeptides, soluble factors 
TLR-2 Lipopeptides, lipoteichoic acid, peptidoglycan 
TLR-3 Double-stranded RNA, polyinosine: cytosine 
TLR-4  LPS, heat-shock protein 60, fusion protein 
TLR-5 Flagellin 
TLR-6  Zymosan, lipopeptides 
TLR-7 Single-stranded viral RNA, imiquimod (R837) 
TLR 8 Single-stranded RNA 
TLR-9 Unmethylated CpG DNA 
TLR-10, TLR-11, TLR-12, 
TLR-13 
Uncertain 
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TLR ligands activate the most important cell types such as antigen-presenting 
cells (APCs), dendritic cells (DCs), macrophages, B cells, and T cells [26]. TLRs 
signaling act via MyD88-dependent (myeloid differentiation primary response 
protein 88) or MyD88-independent pathways [27]. Signaling occurs through the 
adaptor protein MyD88 and its TLR binding partner toll–IL-1 receptor domain-
containing adaptor protein (TIRAP) and induces activation of NF-kB via the Pelle-
like kinase interleukin-1 receptor-associated kinase (IRAK) to activate expression 
of pro-inflammatory genes such as TNF, IL-1ß, IL-6, and IL-8 [28, 29]. 
 
Previous studies have shown that TLR signaling is involved in mucin gene 
regulation. Stimulation of TLR-2 and TLR-3 persuade mucin expression, 
activating mitogen-activated protein kinases (MAPK) and inducing epidermal 
growth factor receptor (EGFR) signaling [30]. Ueno and colleagues showed that 
MUC1 acts as anti-inflammatory agent by negatively regulating TLR-2, -3, -4, -5, 
-7, and -9 mediated inflammatory signaling [31].  
 
In CF, apical expression of TLR-2 and TLR-5 in cystic fibrosis epithelial cells is 
increased and associated with hyper-inflammatory responses to bacterial 
products whereas, surface expression of TLR-4 is reduced and restricted to the 
endosome [32]. 
 
1.3.1 Toll-like receptor-4 
 
TLR-4 is a member of toll-like receptor family of proteins and has been very well 
known for identifying lipopolysaccharide (LPS). TLR-4 ligands also recognize 
several viral proteins, polysaccharides, and a variety of endogenous proteins 
such as low-density lipoprotein, ß-defensin, and heat shock proteins [33]. 
Lipopolysaccharide (LPS) is a component of the outer cell membrane of gram-
negative bacteria such as P. aeruginosa and activates a wide variety of 
mammalian cell types [34]. LPS recognition leads to oligomerization of TLR-4, 
which leads to recruitment of its downstream adaptors through interactions with 
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TIR (Toll-interleukin-1 receptor) domains. The TIR domains play important role in 
TLR-4 mediated signal transductions because any mutation in the TIR domains 
can lead to the elimination of LPS response [35]. Upon recognition of LPS, TLR-4 
has been shown to initiate multiple intracellular signaling events. TLR-4 exhibit 
MyD88-dependent and MyD88-independent (TRIF-dependent) pathway, which 
induces the release of critical pro-inflammatory cytokines such as interleukin-1 
(IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha via 
activation of NF-kB pathways [34]. 
 
In CF, along with bacterial infections, Cohen and Prince stated that the CFTR 
dysfunction affects several components of innate immunity and that the 
initial predisposition to infection in infants with CF may represent a primary defect 
in local mucosal immunity [32]. Studies by Henke et al. have shown that 
defective CFTR cells have reduced TLR-4-mediated innate immune responses 
and decreased interferon-γ inducible protein-10 (IP-10) mediated adaptive 
immune responses in CF. They also postulated that reduced TLR-4 surface 
expression might be due to defective translocation of TLR-4 onto the cell surface 
caused by defective CFTR [36, 37].    
 
Altered processing and localization of TLR-4 on the epithelial cell surface might 
lead to the altered or limited immune responses in CF. Furthermore, the CF 
bronchial airway epithelium may fail early detection of bacterial infection and 
delay of neutrophil chemotaxis and migration across the epithelium. These late 
activations of neutrophils may support the growth and biofilm formation in the CF 
lungs. Neutrophil absence or degradations increase sputum tenacity and are 
associated with reduced muco-ciliary clearance due to the release of large 
amounts of DNA [38-40]. In healthy people, CFTR may also act as pattern 
recognition receptor (PRR) to clear P. aeruginosa infections by activating pro-
inflammatory cytokines. In CF, defective CFTR function leads to impaired muco-
ciliary clearance and results into increased P. aeruginosa, S. aureus, and 
Haemophilus influenzae infections in airway epithelial cells, thereby 
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compromising the clearance ability of the airways of CF patients. It not only 
affects components of innate immunity like a dysregulated TLR-4 trafficking and 
signaling, but also a diminished ability to counteract the oxidative stress induced 
by constitutive and exogenous activated inflammation. This further causes an 
exaggerated and ineffective airway inflammation that fails to eradicate pulmonary 
pathogens and contributes to the persistent airway bacterial infections as seen in 
CF patients (Figure-2). Exact molecular mechanisms or pathways for reduced 
TLR-4 surface expression in CF are still unknown. We believe that reduced TLR-
4 surface expression might be one of major contributor for chronic infections in 
CF. 
                   
 Figure 2: Defective CFTR and TLR-4 dysregulation in CF. 
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1.4 ENaC channel 
 
The epithelial sodium channel (ENaC) or amiloride-sensitive sodium channel is a 
membrane-associated ion channel and plays role in transportation of Na+ ions in 
and out of the cells. It is expressed at the apical plasma membrane of epithelial 
cells in the urinary bladder, lung airway, colon, and ducts of salivary and sweat 
glands [41]. Trans-epithelial Na+ transport is carried out by Na+/K+-ATPase at the 
basolateral membrane of the epithelial cell by creating an electro-chemical 
gradient. This gradient provides the driving force for Na+ influx into the cell via 
ENaC, which mediates the transport of sodium ions (Na+) across the epithelium 
[42]. The movement of Na+ ions across the epithelium establishes the osmatic 
gradient and further accelerates the movement of water in the cells [43]. So, 
active trans-epithelial sodium transport plays an important role in maintaining the 
volume and the composition of epithelial lining fluid across the epithelial cell 
layer. ENaC has been shown to play a crucial role in the electrolyte balance and 
blood pressure regulation [44]. In 1986, Palmer and Frindt first identified the 
single ENaC channel. They studied single channel activity in the apical 
membrane of cortical collecting duct cells from rat kidneys using the patch-clamp 
technique. In 1993, Canessa et al. showed that ENaC consists of α, β and γ 
subunits in rat colon. Each subunit has two membrane-spanning domains with a 
large extracellular loop, intracellular N-terminal, and C-terminal. The activity of 
ENaC is regulated by many extrinsic and intrinsic factors. Extrinsic factors are 
hormone activation, mechanical stretch, and/or proteolytic cleavage. While, 
intrinsic factors include intracellular trafficking, ubiquitination, various kinases, 
sodium, and metabolic substrates. These factors affect the regulation of ENaC 
channel expression/synthesis, intracellular channel trafficking, and single-
channel properties such as open probability (Po) [45]. Amiloride is a potassium-
sparing diuretic and is very well known to block the activity of ENaC [42]. 
 
Epithelial sodium channel plays a crucial role in maintaining lung fluid balance by 
transportation of Na+ ions across the lung epithelium. ENaC channel in the lungs, 
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alveolar type II cells and airways epithelial cells appear to be involved in the 
regulation of sodium transport [46]. In addition, the functional evidence from 
Hummler and colleagues demonstrated that genetically knocking out αENaC in 
mice is associated with defective lung fluid clearance and results in the 
premature deaths of newborn mice [47]. In contrast, airway epithelial cells absorb 
Na+ ions and actively secrete chloride/bicarbonate ions to maintain the volume of 
airways surface liquid (ASL) levels and composition. The airway surface liquid is 
composed of the peri-ciliary layer (PCL) and mucus layer which play important 
role in bacterial clearance. ENaC and CFTR channels regulate critical 
components of muco-ciliary clearance (MCC) such as PCL height, viscosity, and 
pH. Impaired MCC leads to chronic bacterial infections and exaggerated 
inflammatory responses in many diseases including CF and chronic obstructive 
pulmonary disease (COPD) (Fig.3). 
 
It has been shown that amiloride-sensitive epithelial Na+ ions are increased in CF 
airways epithelia, which might be due to defective CFTR in CF [48]. Loss of 
CFTR functions lead to dysregulated ENaC channel [49] and mutation in the β-
subunit of ENaC is correlated to severe CF-like symptoms [50].  
 
CFTR is a negative regulator of ENaC, although the exact mechanism of how 
CFTR regulates ENaC is still unknown. The idea that CF is a result of 
dysregulation of ion channels including CFTR and ENaC channels, which is 
associated with Na+ ions hyperabsorption and Cl- ions reduction. This further 
lead to the formation of contracted viscous surface liquid layer causing muco-
ciliary transport defects, bacterial infections, inflammatory responses, and 
eventually lung failure. Several factors such as lipopolysaccharide, protein kinase 
C, reactive oxygen species (ROS) and hypoxic stress, are involved in regulation 
of ENaC activity [51]. ENaC-blocking is thought to facilitate restoration of the 
airway surface liquid volume and subsequently allow normal muco-ciliary 
clearance, which might be interesting therapy in the management of lung disease 
in CF patients [52].  
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 Figure 3: CFTR and ENaC regulation in CF [53] 
 
Recent literature showed that transforming growth factor-β (TGF-β), a 
multifunctional cytokine, regulates the immune, inflammatory systems and 
downregulates ENaC channels in acute lung injury (ALI) [54]. It is also shown 
that microRNAs (miRNAs), a major class of gene expression regulator, is 
involved in ENaC regulation. miR-16 has been reported to downregulate ENaC 
channel through inhibition of serotonin transporter (SERT), which is involved in 
the 5-HT transmitter system and downregulate TGF-β in alveolar type II cells of 
ALI [55]. 
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1.5 Transforming growth factor-β  
 
TGF-β was first identified by Richard K. Assoian and his colleagues in 1983 [56]. 
It is derived from human platelets, hence known as platelet-derived TGF-β. It 
consists of two subunits of 12.5 kDa each, which are bound with disulfide bonds 
[56]. Up to date, several isoforms of TGF-β have been determined. It is 
considered as a multifunctional cytokine. Currently, TGF-β family consists of 
more than 60 structurally related members including five activins, eight bone
morphogenic proteins (BMPs) and three TGF-βs [57]. These members play an 
important role in the regulation of multiple cellular functions, including cell 
proliferation, cellular differentiation, cell migration, organization, and apoptosis 
[58]. The three isoforms of TGF-β are TGF-β1, 2 and 3, which contains around 
40 different related proteins [59]. TGF-β is synthesized as a latent precursor 
molecule (LTGF-β), which consists of an amino-terminal hydrophobic signal 
peptide region, the latency associated peptide (LAP) region and the C-terminal 
potentially bioactive region. TGF-β related proteins are categorized into 2 
subfamilies: TGF-β/activin/nodal subfamily and the bone morphogenetic protein 
(BMP)/growth/differentiation factor (GDF)/Muellerian inhibiting substance (MIS) 
subfamily [59]. These subfamilies play a diverse role in the regulation of cellular 
functions in embryonic development, tissue homeostasis, tissue repair 
remodeling as well as disease pathogenesis [60, 61].  
 
In human lungs, TGF-β is expressed in multiple cells types such as airway 
epithelium, alveolar macrophages, endothelial and mesenchymal cells [62, 63]. 
TGF-β is secreted in a latent form, which complexes with two polypeptides, latent
TGF-beta binding protein (LTBP) and latency-associated peptide (LAP). TGF-β 
signal transduction is initiated by binding of TGF-β to its serine/threonine kinase 
receptors namely, the type II (TβRII) and type I (TβRI) receptors on the cell 
membrane. Upon ligand binding, TβRII activates TβRI by phosphorylation of 
threonine and serine residues on TβRI. Further, the activated TβRI activates 
SMAD family messenger. SMAD family is the family of intracellular proteins, 
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which play important role in extracellular signaling for activation of TGF-β 
pathways. These are categorized in 3 different classes such as receptor-
regulated SMADs (R-SMADs) which include SMAD1, SMAD2, SMAD3, SMAD5 
and SMAD8/9 [64], common partner SMADs (Co-SMADs) which includes only 
SMAD4 [65] and inhibitory SMAD (I-SMAD) which includes SMAD6 and SMAD7 
[66]. Activated TβRI phosphorylates the R-SMAD, SMAD2/3 which are coupled 
to co-SMAD SMAD4 to form a heterocomplex. These complexes enter the 
nucleus and regulate the target gene transcription. TGF-β receptors can also 
lead to ubiquitination-mediated degradation with the help of inhibitory 
SMADs. SMAD-7 acts as an inhibitor to block the phosphorylation of R-SMADs 
[67]. A schematic overview of TGF-β signaling is presented in Fig.4 adapted from 
[68]. 
 
 
Figure 4: TGF-β signaling pathways [68] 
 
TGF-β levels in plasma from CF patients were found to be elevated compared to 
controls [69]. Also, TGF-β levels were increased in bronchoalveolar lavage fluid 
(BAL) from children with CF and it was shown to be associated with neutrophilic 
inflammation with reduced lung function [70]. Further, TGF-β signaling is 
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significantly increased in lung tissue sections from CF patients [71]. Previous 
data also suggested the role of TGF-β in downregulation of CFTR channels in CF 
[72]. Contradictory to this, TGF-β is known as crucial ENaC channel blocker and 
shown to inhibit the ENaC channel in ALI [54, 55, 73].  
1.6 microRNAs  
 
miRNA is an epigenetic modification and novel approach towards understanding 
various gene expression in infections and diseases. The first miRNA (lin-4) was 
discovered in 1993 in Caenorhabditis elegans. Further, let-7 was discovered in 
human in 2000 [74]. Currently, there are 24,521 precursor miRNA expressing 
30,424 mature miRNAs [75]. miRNA is small, non-coding single-stranded RNA, 
consisting of 19-25 nucleotides and has been shown to play role in gene 
regulation by transcription repression, which involves various biological 
processes such as, cellular differentiation, cell cycle regulation and metabolism 
[76-78]. MicroRNA is transcribed in the nucleus as distinct transcription unit by 
RNA polymerase II or III. It is then subjected to the formation of a long fragment 
of double-stranded hairpin structured RNA, which is called as primary miRNA 
(pri-miRNA). Then Drosha, a RNase type III enzyme and RNA-binding protein 
DGCR8 process the pri-miRNA to form ~60-100 nucleotide long hairpin-
structured precursor miRNA (pre-miRNA). After pre-miRNA formation, exportin 5 
and RAN-GTP export the pre-miRNA from the nucleus to cytoplasm. Dicer, which 
is RNAse III endonuclease, processes pre-miRNA and leads to the formation of a 
22 nucleotides double stranded RNA molecule called miRNA/miRNA duplex.
Further, these duplex form a mature single stranded RNA which is incorporated 
into RNA-induced silencing complex (RISC) consisting of dicer, TRBP, and 
argonaute protein (Figure-5) [79]. Finally, This RISC complex identifies the target 
mRNA sequence, binds it and leads to gene silencing by transcription repression 
or degradation of target mRNA sequences.  
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Figure 5: The formation and fate of a microRNA [80] 
 
1.6.1 microRNAs in cystic fibrosis  
 
Previously reported studies revealed the impacts of miRNAs on the development 
of lung diseases including chronic obstructive pulmonary disease (COPD), 
asthma, lung inflammation and cystic fibrosis [81]. Since defective CFTR and 
chronic inflammation are the major features of CF, miRNAs might play an 
important role in the regulation of CFTR, inflammation, innate immune response, 
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endoplasmic reticulum stress, lung cell development and differentiation. miRNAs 
could downregulate CFTR expression by binding to the 3′-UTR segment of the 
transcript, which was firstly shown by Gillen et al. in 2011 [82]. They identified 13 
miRNAs, which could regulate CFTR expression in various cells lines. Further, 
miRNAs such as miR-145, miR-223, and miR-494 have been shown to be up-
regulated in CF bronchial epithelial cells suggesting a role in repression of CFTR 
gene in cystic fibrosis bronchial epithelial cells (CFBE cells) [83]. Furthermore, 
the role of miR-101, miR-144, and miR-145 in downregulation of CFTR gene 
expression was confirmed in 16HBE14o- cell line and in primary human airway 
cells [84].  
 
In response to innate immunity and inflammation, Oglesby and colleague 
performed first miRNAs profiling on bronchial brushing of CF patients. They 
identified 92 differential expressed miRNAs of which 56 were down-regulated 
and 36 were up-regulated. In this study, it was found that miR-126 was 
significantly reduced in lungs of patients with CF as compared to that of healthy 
controls, which is correlated with a significant up-regulation of TOM-1 mRNA. 
 
Target of Myb protein-1 (TOM-1) acts as an anti-inflammatory agent by 
negatively regulating NF-kB, TLR-2, TLR-4, and IL-1β induced signaling 
pathways in CFBE cells [85]. The second miRNA is miR-155, which was found to 
be up-regulated in lung epithelial cells and neutrophils from patients with CF and 
associated with activation of IL-8 dependent inflammation via PI3K/Akt signaling 
pathway. Further studies also confirmed that exposure of the anti-inflammatory 
cytokine IL-10 or following inhibition of IL-1β signaling result into reduced levels 
of miR-155 with a reduction of IL-8 production [86].  
 
As discussed earlier, defective CFTR leads to ENaC over-expression. Recently 
published data suggest the role of miRNAs in ENaC regulation. Studies by 
Tamarapu et al. demonstrated that miR-16 suppresses the expression of TGF-β, 
thereby indirectly leading to the up-regulation of ENaC expression in ALI [55]. As 
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TGF-β is known to inhibit the expression of ENaC [73], miR-16 seems to rescue 
F508del-CFTR function in native cystic fibrosis epithelial cells [87]. 
 
miRNAs can be used as therapeutics by 2 methods which include inhibition of 
miRNA by its artificially made componentry sequence also called as anti-
oligonucleotide (anti-miR). When delivered to the cells, anti-miR binds to target 
miRNA and relieves inhibition of endogenous target genes. Sometimes it can 
also degrade the target miRNA. The second method is supplementation of 
miRNA in which artificially made miRNA also called as miRNA-mimic is used to 
suppress the expression of endogenous genes [88].  
 
miRNA that targets IL-8 have the potential to decrease IL-8 expression and 
correct the over exuberant neutrophils influx in CF. In contrast, inhibition of 
miRNA such as miR-145, miR-223 and miR494 using anti-miR approach, 
aberrant CFTR expression might be corrected and chloride ion conductance can 
be restored. So, finding and targeting miRNAs can provide a newly emerging 
field in the regulation of innate immunity, inflammation, and correction of CFTR in 
CF. However, there are some challenges such as numerous molecular targets 
for miRNA, tissue-specific delivery, degradation by nucleases optimal chemistry 
and delivery systems have to be developed. 
 
1.7 Iron homeostasis  
 
Iron is a redox active metal which is essential for the normal function of a wide 
range of cellular proteins [89]. Iron shuttles between two oxidation states, Fe (II) 
(Fe2+; ferrous iron) and Fe (III) (Fe3+; ferric iron). Fe2+ is very aqua soluble and 
is transported across the membranes. However, Fe2+ is easily oxidized to the 
Fe3+, which is highly insoluble at physiological pH. Many proteins bind iron in its 
Fe3+ form. Fe3+ is relatively non-toxic. However, Fe2+ is a potent pro-oxidant 
and free iron generates ROS via the Fenton or the Haber-Weiss reaction 
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rendering it into quite toxic form [90-92]. Cells of the lungs obtain their iron 
supplies from the plasma, where it is bound to the protein transferrin (Tf). Most 
of the iron delivered to cells is imported via transferrin receptor-1 (TfR-1), but 
may also be utilized by nonreceptor-mediated mechanisms [93, 94]. 
Intracellular iron is also supplied by hemeoxygenase-1 (HO-1) via conversion of 
heme into the equal concentration of Fe2+, carbon monoxide, and biliverdin. 
Intracellular iron is stored in a non-toxic form within ferritin [95]. Stored iron can 
be exported via the only known iron exporter ferroportin (FPN). Airway epithelial 
cells up-regulate FPN expression in the presence of iron, and FPN is thought to 
play a role in lung iron detoxification [96, 97]. Many proteins are involved in iron 
transport and regulation, such as divalent metal transporter-1 (DMT-1), 
hephestin, transferrin receptor-2 (TFR-2), ferroportin (FPN), hepcidin, duodenal 
cytochrome b (DCYTB), hemojuvelin (HJV) and heme carrier protein 1 (HCP1) 
[98]. Most proteins associated with iron metabolism are expressed in the lung 
and are likely to play important role in lung health and lung defense [99-102].  
These iron-associated proteins are synthesized in the lung mainly by two types 
of cells, the airway epithelial cells and the alveolar macrophages (AM). Airway 
epithelial cells serve as the first line of defense in the upper airways against 
harmful environmental insults, including toxic heavy-metal-containing particles 
and very efficient in removing non-transferrin-bound iron, which converts it to 
less toxic protein-bound iron. 
 
CF airways contain large amounts of iron and ferritin during acute 
exacerbations or non-acute form [103]. Moreau-Marquis and colleagues 
demonstrated that airway epithelial cells expressing ΔF508-CFTR releases 
more iron into the extracellular medium than the cells expressing wild-type 
protein [104]. As discussed earlier, CF is involved in dysregulation of ion 
channels including ENaC channel, which is responsible for the transportation of 
Na+ ions into the cell. Turi et al. suggested that epithelial transport of Na+ ions 
into the cell is associated with transcellular movement of metals, particularly 
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iron [105]. Vice versa, iron itself can induce ENaC expression and amiloride-
sensitive Na+ transport in fetal lung epithelial cells [106]. Supporting to this data 
Henke et. al. confirmed the increase of intracellular iron which further lead to 
impaired hypoxia-inducible factor-1 causing the downregulation of 
hemeoxygenase-1 expression in CF epithelial cells [107]. Downregulation of 
HO-1 is associated with iron accumulation in multiple cell types. Increased iron-
mediated ROS might alter the microenvironment of airways epithelial cells in 
chronic CF, thereby leading to low partial pressure of oxygen inside the lungs 
and thus causing hypoxia [108, 109].  
 
1.7.1 Hypoxia-inducible factor-1α 
 
HIF-1α is a transcription factor, which is activated in response to hypoxia and is 
controlled at the protein level, through enzymes called prolyl hydroxylases 
(PHDs). This enzyme continuously targets HIF-1α for proteasomal degradation 
[110]. Importantly, iron is required for activation of PHD, which play a crucial 
role in the degradation of HIF-1α in normoxic condition [110]. It was shown that 
HIF-1α expression is up-regulated via NF-κB [111, 112] and TLR-4 [113]. 
Further, it was shown that HIF-1α enhanced the expression of TLR-4 mRNA 
and protein. HIF-1α mediated up-regulation of TLR-4 expression enhances the 
cellular response to LPS resulting in increased expression of IL-6 and 
interferon-γ-inducible protein-10 (IP-10) [114]. 
 
HIFs are major regulators of several genes involved in iron homeostasis and 
inflammation, which includes TfR-1, hemeoxygenase-1, natural resistance-
associated macrophage protein-1 (Nramp-1), DMT-1, erythropoietin, and 
ferroportin [115]. 
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1.7.2 Ferroportin 
 
Ferroportin (FPN) is a transmembrane protein encoded by FERROPORTIN 
(SLC40A1), which transports iron from inside to outside of the cell. It is the only 
known iron exporter and plays a crucial role in maintaining iron homeostasis. 
Mutation or lack of ferroportin leads to iron accumulation, which further causes 
iron overload in the cells. The regulations of FPN can be carried out by 
transcriptional, post-transcriptional, and post-translational manner [116].  
 
At transcription level factors like transition metals, heme, inflammatory cytokines 
and hypoxia have been shown to be involved in regulation of ferroportin. Iron-
responsive element (IRE) at FPN mRNA is involved in post-transcription 
regulation [117]. Post-translational regulation of FPN is associated with the iron 
regulatory hormone hepcidin, which plays a crucial role in ferroportin 
internalization and degradation [116]. 
 
The ferroprtin expression has been shown to be up-regulated in lung tissue from 
CF patients [118]. Up to date, the area of studies, which emphasize on the 
relation between FPN and CF has not been explored. It will be interesting to 
understand molecular pathways and its involvement in the altering iron 
homeostasis in CF. 
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1.8 Hypothesis and aims: 
The reduced TLR-4 surface expression might be responsible for a reduced 
detection of gram-negative bacteria (for example Pseudomonas aeruginosa) and 
causing worsening of CF. Therefore, identifying the molecular mechanism and 
the factors involved in TLR-4 trafficking might assist to resolve the immune 
response in CF (Figure. 6).  
 
 
 
Figure 6: Schematic representation of factors which might involve in TLR-4 and 
ferroportin expression in CF.  
 
Study goals based on the hypothesis: 
1. To analyze expression of TGF-β and its regulating factors in CFBE41o- 
and 16HBE14o-cells. 
2.  The role of miR-16 in TGF-β regulation in CF. 
3.  To evaluate ferroportin expression and its regulating factors in CFBE41o- 
and 16HBE14o- cells. 
4.  To identify TGF-β mediated iron-related proteins (FPN) and TLR-4 
expression in CFBE41o- and 16HBE14o- cells. 
5.  To investigate the effect of ENaC inhibition on FPN and TLR-4 expression 
in CFBE41o- and 16HBE14o-cells. 
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2 Materials and methods 
2.1 Materials 
2.1.1  Chemicals and biochemicals 
 
Table 2: Chemicals and biochemicals 
Reagents Company 
2,2’-dipyridyl Sigma-Aldrich 
Acetic acid Carl Roth 
Ammonium persulfate Carl Roth 
Bovine serum albumin 30% solution PAA 
β mercaptoethanol  Sigma, USA 
Bromophenol blue Carl Roth 
BSA solution (2mg/mL) Bio-Rad, USA Bio-Rad, USA 
Chloroform  Carl Roth, Germany 
Calcium chloride Sigma-Aldrich 
Clarity western ECL substrate Bio-Rad 
DAPI  Invitrogen, USA 
DFO Sigma, USA 
Dimethyl sulfoxide  Sigma, USA 
DNA ladder (100bp,1Kb)  Fermentas, Germany 
D(+)-saccharose Carl Roth 
Developer AGFA 
EDTA Carl Roth 
EIPA Sigma-Aldrich 
Ethanol absolute Sigma-Aldrich 
Fluorescence mounting medium  Dako, Germany 
Glycerol Merck 
Glycine Carl Roth 
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Hydrochloric acid 37% Sigma-Aldrich 
Iron (II) sulphate heptahydrate Carl Roth 
Isol-RNA lysis reagent VWR 
Isopropanol Sigma-Aldrich 
LPS from PA Sigma-Aldrich 
Lipofectamine 2000  Invitrogen, USA 
Milk powder Merck 
Manual fixing bath AGFA 
Mercaptoethanol Sigma-Aldrich 
Methanol Sigma-Aldrich 
N,N,N´,N´-tetramethyl-1,2-diaminomethane 
(TEMED) 
Sigma, USA 
Ponceau S solutionA  Sigma, US 
Potassium dihydrogen phosphate  Carl Roth, Germany 
Potassium phosphate monobasic  Carl Roth, Germany 
PageRuler prestained protein ladder 10-170kDa Thermo Scientific 
PBS 1x Gibco 
Penicillin-streptomycin Gibco 
Pierce BCA protein assay reagent A Thermo Scientific 
Pierce BCA protein assay reagent B Thermo Scientific 
PMSF Carl Roth 
Primers Eurofins 
Rotiphorese® Gel 30 Carl Roth 
SDS Carl Roth 
Sodium chloride Sigma-Aldrich 
Sodium hydroxide standard solution (4M) Sigma-Aldrich 
Supersignal west Femto maximum sensitivity 
chemiluminescent substrate 
Pierce 
SYBR® green PCR master mix Life Technologies 
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TaqMan® fast advanced master mix Life Technologies 
TaqMan® microRNA RT kit Life Technologies 
TEMED Sigma-Aldrich 
Tris Carl Roth 
Triton-X-100 Sigma-Aldrich 
Trypsin/EDTA(1x) Gibco 
Tryptone Sigma-Aldrich 
Tween® 20  Carl Roth 
Western blotting luminol reagent Bio-Rad  
Xylol  Carl Roth, Germany 
 
2.1.2 Instruments and software’s 
Table 3: Instruments and Manufacturer 
Instrument Manufacturer 
AccuBlock™ digital dry baths Labnet Internationals 
Amersham hybon-p (PVDF transfer 
membrane) 
GE Health Care 
Analytical balance John Morris Scientific 
Autoclave Systec 
Centrifuge (table top) Heraeus Instruments 
Filtropur S 0.2 (sterile filters) Sarstedt 
Incubator Heraeus Instruments 
Infinite® 200 PRO Tecan 
Inkjet syringe (20 mL) Braun 
MicroAmp® fast optical 96-well reaction plate Applied Biosystems 
MicroAmp® optical adhesive film Applied Biosystems 
Mini-PROTEAN® tetra cell Bio-Rad 
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Mini spin table centrifuge Kobe 
Nanodrop spectrophotometer peQLab Biotechnology 
PCR system PE Applied Biosystems 
PowerPac™ HC power supply system Bio-Rad 
Roller Kobe 
SevenCompact™ pH/ion Mettler Toledo 
Shaker    Kobe 
Sonifier Branson 
Trans-blot SD system Bio-Rad 
ViiA™ 7 real-time PCR system Applied Biosystems 
Vortex-Genie 2 Scientific Industries 
ImageJ  National Institutes of Health USA 
Graph Pad Prism  GraphPad Software, La Jolla, 
USA 
Leica application suite advanced 
fluorescence (LAS AF) software 
Leica Mikrosysteme Vertrieb 
GmbH 
 
2.1.3 Primary and secondary antibodies: 
Table 4: Antibodies and companies 
Antibody Company 
Immunoblotting 
Anti-goat immunoglobulins Dako 
Anti-HIF 1α antibody Life Span Biosciences 
Anti-FPN antibody Nivus Bio 
Anti-FPN antibody Santa Cruz Biotechnology 
Anti-mouse immunoglobulins Dako 
Anti-rabbit immunoglobulins Dako 
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Anti- TGF-β antibody Santa Cruz Biotechnology 
Anti-TLR-4 antibody Abcam 
Anti-TLR-4 antibody Santa Cruz Biotechnology 
Anti-β-actin antibody Sigma-Aldrich 
Immunofluorescence 
Donkey anti-rabbit 488 green alexafluor® 
488 
Invitrogen 
Donkey anti-rabbit 594 green alexafluor® 
594 
Invitrogen 
Donkey anti-rabbit 594 mouse alexafluor® 
594 
Invitrogen 
 
2.1.4 Medium and serums 
Table 5: Media and companies 
Medium Company 
DMEM/HAM’s F12 growth medium Promocell 
MEM with L-glutamine Gibco 
Opti-MEM Gibco 
Fetal calf serum  Gibco 
Bovine serum albumin  Thermo Scientific, Rockford, IL, 
USA 
 
2.1.5  Kits 
Table 6: Kits and suppliers 
Kits Suppliers 
cDNA reverse transcription kits Applied Biosystems Carlsbad, 
CA 
 
37 
 
MATERIALS AND METHODS 
 
  
GeneAmp RNA PCR kit applied biosystems, 
carlsbad, CA 
 
Applied Biosystems, Carlsbad, 
CA 
 
Pierce BCA protein assay kit Thermo Scientific, Rockford, IL, 
USA 
 
Clarity™ western ECL blotting substrate 
 
Bio-rad Germany 
ZytoChem plus broad spectrum 
 
Zytomed systems 
DuoSet® ELISA development systems R&D Systems, USA 
 
2.1.6 Miscellaneous   
Table 7: products and companies 
Name Company 
6-well culture plate, sterile Greiner Bio-One 
12-well culture plate, sterile Greiner Bio-One 
Amersham hybon-p (PVDF transfer 
membrane) 
GE Health Care 
Cell scrapers 16cm 2-position blade Sarstedt 
Conical tubes BD FalconTM 
Culture slide 8-well BD FalconTM 
Deoxynucleotide set, 100mM Sigma-Aldrich 
Disposable cuvettes plastibrand® Carl Roth 
Dual-luciferase reporter assay system Promega 
Eppendorf pipettes Eppendorf 
Eppendorf safe-lock tubes Eppendorf 
Eppendorf phase-lock tubes Eppendorf 
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Filtropur syringe filter 0.20μM sterile Sarstedt 
Nunc immunoplate F96 Maxi sorp nunc Sigma-Aldrich 
Parafilm Pechiney 
Pasteur pipette Hirschman 
Pipette tips Tip-One 
Röhren tubes Sarstedt 
Serological pipettes Greiner Bio-One 
Thermo Scientific CL-XPosure film Pierce 
Thin-walled PCR tubes 600µL Stratagene 
Tissue culture dish 100X20mm Sarstedt 
Whatman blotting paper Whatman 
 
2.1.7 Buffers and Solutions 
2.1.7.1 1-Buffers for SDS-PAGE and Electrophoresis 
Table 8: Buffers and Compositions 
Buffers Composition 
Protein extraction (lysis buffer) 
Lysis buffer 
50mM tris 
150mM NaCl 
5mM EDTA 
1% triton-X-100 
0.5% Na-deoxycholate 
1mM PMSF (100mM PMSF stock) 
 
 
Resolving gel buffer 1.125M tris 
HCl pH 8.8 
30% saccharose 
volume make up to 100 mL  
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Stacking gel buffer 0.625M tris 
HCl pH 6.8 
volume make up to 250 mL 
 
4X loading buffer 5g of SDS 
25 mL stacking gel buffer  
40 mL glycerol   
0.005g Bromophenol blue  
Adjust the volume up to 100 mL with 
distilled water 
 
Running buffer 30g tris 
144g glycine 
10g SDS 
 
Transfer buffer 20mM tris 
159mM glycine 
20% MeOH 
 
Blocking buffer 5% milk powder in 1xTBST 
TBST washing buffer 0.5M NaCl 
0.5M tris 
HCl pH 7.5 
20g tween20 (after adjusting pH) 
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2.1.7.2 2 Buffers for immunofluorescence  
Reagents Composition 
4% paraformaldehyde 4 g PFA dissolve in 100 mL PBS (add 
few drops of NaOH). Heat at 55°C until 
PFA is dissolved. Cool and adjust the 
pH to 6-7 
 
0.1% saponin  
1% BSA 1g of BSA in 100mL PBS 
 
2.1.7.3 3 Buffers for immunohistochemistry 
 Reagents Composition 
PBS 8 g NaCl 
0.2 g KCl 
1.44 g Na2HPO4 
0.24 g KH2PO4 
Dissolve in 800 mL of dH2O,  
adjust pH to7.4 and add H2O q.s. to 1 l 
 
Antigen retrieval buffer 
 
2.49 g of sodium citrate 
800mL of H2O and adjust the pH to 6 
500 µL Triton-x-100 
Add H2O q.s to 1l 
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2.1.7.4 4 Buffers for ELISA 
Reagents Composition 
Phosphate buffered saline (PBS) 137mM NaCl,  
1.5mM KH2PO4, 
8.1mM Na2HPO4·2H2O,  
2.7mM KCl,  
diluted with distilled water to a final 
volume of 1 liter 
pH=7.4,  
0.2μM filtered 
Wash buffer 0.05% Tween 20 in PBS,  
pH=7.2-7.4 
Block buffer 5% Tween 20 in PBS 
Reagent diluent 1.4% delipidized BSA,  
0.05 % Tween 20 in PBS  
pH=7.2-7.4,  
0.2 μM filtered 
Stop solution  2 N sulfuric acid 
 
2.1.8 Primers of mRNA 
Table 9: Primers and sequences 
Genes Tm Sequence 
FERROPORTIN 
SLC40A1 
58.68 
58.37 
F-CTACTTGGGGAGATCGGATGT 
R-CTGGGCCACTTTAAGTCTAGC 
α-ENaC 66.9 
69.7 
F-GGTGGACTGGAAGGACTGGAAGATCG 
R-ATGAAGTTGCCCAGCGTGTCCTCCTC 
TGF-ß 59.8 
61.9 
F-CCCAGCATCTGCAAAGCTC 
R-GTCAATGTACAGCTGCCGCA 
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2.1.9 Primers for miRNA  
Table 10: miRNA primers and company 
miRNA Company 
hsa-miR-16 Applied Biosystems 
 
2.1.10  Cell lines  
Table 11: cell lines  
Cell line Description  
16HBE14o- Human Bronchial epithelial cell line 
CFBE41o- Cystic Fibrosis Bronchial Epithelial cell line  
corrCFBE41o- Corrected Cystic Fibrosis Bronchial Epithelial cell 
line 
 
2.2 Methods 
2.2.1 Cell culture 
 
Cystic fibrosis bronchial epithelial cell line (CFBE41o-), with homozygous DF508- 
CFTR, its isogenic wild-type CFTR-complemented counterpart (corrCFBE41o-) 
and normal human bronchial epithelial cell lines (16HBE14o-) were received from 
Dr. Dieter Gruenert. 
 
Cells were sub-cultured on tissue culture plastic plate coated with a solution 
containing fibronectin (BD Biosciences, San Diego, CA) and grown in Minimum 
Essential Medium (MEM) with Earl’s salts (Gibco, Karlsruhe, Germany), 
supplemented with 10% fetal calf serum (FCS; Gibco) and 1% 
Penicillin/Streptomycin (PAA, Pasching, Austria) at 37°C in 5% CO2. 
Complemented CF airway epithelial cells (corrCFBE41o-) were cultivated in 
medium containing 200 mg/mL Hygromycin B (Invitrogen, Carlsbad, CA). The 
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cells were maintained in 10 cm2 flasks at 37°C incubator. Upon confluence, cells 
were sub-cultured in a ratio of 1:3 or counted by using hemocytometer for spilled 
according to numbers of cells. 
 
Cells were either treated with Transforming Growth Factor-β1 (TGF-β1) Human 
Recombinant Protein (EMD Millipore), Deferoxamine mesylate salt (DFO, Sigma-
Aldrich) and 5-(N-Ethyl-N-isopropyl) amiloride (EIPA, Sigma-Aldrich). Controls 
were treated with PBS or respective vehicles. Cells were reversed transfected 
with miR-16 Mimics and anti-MiR 16 using, siPORT (Ambion). 
 
2.2.2 RNA analysis  
2.2.2.1  RNA isolation 
RNA isolation was carried out to analyze mRNA expression and miRNA 
expression. Trizol method (VWR Germany) was used for the RNA isolation. Cells 
media was removed from the plate followed by PBS washing. 1mL of trizol was 
added to the plate and collected into 1.5 mL tube. Cell lysate with trizol was 
immediately frozen and stored in -80°C freezer until the further procedure.  
 
Samples were thawed and 200uL ice-cold chloroform was added to each 
sample. Sample tubes were inverted 15-20 times and kept for 3 min at RT and 
centrifuged (pre-cooled) at 13000 rpm for 15 min at 4°. The upper aqueous 
phase (300-400µL) was transferred to a new tube and repeated the step one 
more time. Further, the upper aqueous phase was transferred to a new tube and 
1µL of glycoblue and 500µL of pre-cooled isopropanol was added to each tube 
followed by gentle inverting for 3-5 times. Samples were stored in -800C for 
overnight. Following day, the samples were centrifuged for RNA pelleting at 
13,000 rpm for 30 min at 4°C. Supernatants were discarded and the blue colored 
pellet was washed twice with 1mL of 75% ice-cold ethanol and centrifuged at 
10,000 rpm for 15 min at 4°C. All ethanol was removed and the pellets were left 
to air dry at 52oC. RNA was dissolved in 30µL of RNAse free water. RNA 
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concentrations of samples were measured by using the Nano-Drop 2000c 
photometer (PeqLab). 
 
2.2.2.2 cDNA synthesis 
 
It is processed for the synthesis of single-stranded DNA (complementary DNA or 
cDNA) from RNA template by reverse transcription. After measuring RNA 
concentration, a volume equivalent to 1 μg of RNA was added to DNAse free 
water to make a total of 15µL volume. A master mix of 5µL was prepared from 
High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems) as follows: 
Table 12: cDNA synthesis reaction mix 
Reagents Volume taken 
10x PCR Buffer II 2µL 
25x dNTPs 0.8µL 
10✕ RT Random Primers 2µL 
MultiScribe™ Reverse Transcriptase 1µL 
RNase Inhibitor 1µL 
ddH2O 3.2µL 
Total 10 µL 
 
The 10x PCR Buffer II need for the maintaining optimal pH and ionic strength for 
PCR amplification. The dNTPs include of dATP, dCTP, dGTP, and dTTP. 
Random Hexamer primers used as short oligodeoxyribonucleotides of random 
sequence, which annealed to random complementary sites on a target RNA to 
help for cDNA synthesis by reverse transcriptase. RNase Inhibitor (ribonuclease 
inhibitor) was used to prevent the degradation of RNA template by inhibiting the 
RNase activity. MultiScribe™ Reverse Transcriptase in the master mix was a 
recombinant RNA-dependent DNA polymerase for synthesizes a complementary 
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DNA (cDNA) strand. The reaction was carried out PCR cycler (Bio-Rad) by 
following the steps in the program: 
Table 13: PCR program for cDNA synthesis 
Conditions Step-1 Step-2 Step-3 Step-4 
Temperature (°C) 25 37 85 4 
Time (min) 10 120 5 ∞ 
 
The cDNA was cooled down to 4 °C, and stored at -80°C. 
 
2.2.2.3 Amplification of cDNA 
 
Quantitative real-time PCR was performed using SYBR Green qPCR master mix 
(Applied Biosystems, Darmstadt, Germany) on a StepOnePlus™ 96 well Real-
Time PCR System (Applied Biosystems, Carlsbad, CA). Generated cDNA was 
used as a template for amplification in q-PCR. β-actin was used as a reference 
housekeeping gene in all q-PCR reactions. Real-time PCR data were analyzed 
using the comparative cycle threshold (Cq: amplification cycle number) method. 
The amount of target gene was normalized to the housekeeping gene β actin 
(ΔCq). Relative differences were determined using the equation 2 (-ΔΔCq). 
Primers were generated using Primer 3 software. For PCR master mix, the 
following reagents were added to cDNA-Template 2µL to a total volume of 25µL: 
Table 14: qPCR reaction mix for mRNA expression 
Reagents Volume taken (µL) 
SYBR Green Buffer 12 
Primer forward 1 
Primer reversed 1 
dH2O 4 
cDNA template 2 
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Total 20 
 
SYBR Green buffer mix consists of pre-mixed SYBR green I fluorescent dye, 
magnesium ion, uracil-DNA glycosylase (UDG), proprietary stabilizers, and 
deoxyribonucleotide triphosphates (dNTPs) and Taq DNA polymerase. SYBR 
green I was a fluorescent dye that binds directly to double-stranded DNA 
(dsDNA). Primers were designed which were 20-22 base pairs longs with 40-
60% GC content and with 57 to 60°C melting temperature. A negative control 
was containing water instead of the template DNA. The PCR was performed in 
Step One plus PCR system using the following program: 
 
Table 15: qPCR program for mRNA expression analysis 
Cycle step Temperature (°C) Time  Cycles 
Initial 
Denaturation 
94 10 m 1 
Denaturation 95 15 s 40 
Annealing 60 1 m 
Extension 72 30 s 
Final extension 72 4 m 1 
 
2.2.2.4 cDNA synthesis for miRNA expression  
 
For miRNA expression analysis, RNA samples were diluted to the 2ng and the 
following PCR master mix was prepared to transcribe RNA into cDNA (Applied 
Biosystems® TaqMan® MicroRNA reverse transcription kit and TaqMan® 
MicroRNA assays) 
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Table 16: miRNA RT- PCR master mix recipe for cDNA 
Component Volume/reaction 
100 mM dNTPs 0.15 µL 
MultiScribe™ reverse transcriptase, 50 
U/µL 
1.00 µL 
10x reverse transcription buffer 1.50 µL 
RNase inhibitor, 20 U/µL 0.19 µL 
Nuclease-free water 4.16 µL 
Total volume 7.00 µL 
 
In above master mix, 3 µL of 5x RT primer provided in the TaqMan® MicroRNA 
assay and 5 µL of 2ng RNA were added. All the components were mixed gently 
and centrifuged. The reaction was carried out PCR cycler (Bio-Rad) by following 
the steps in the program: 
Table 17: PCR program for cDNA for miRNA 
Conditions Step-1 Step-2 Step-3 Step-4 
Temperature (°C) 25 37 85 4 
Time (min) 10 120 5 ∞ 
 
2.2.2.5 Quantitative Real-Time PCR analyzes for miRNA profiling: 
qRT PCR was performed on an Applied Biosystems® ViiA™ 7 System, a 7th 
generation real-time PCR system in a 96-well format. The qRT PCR was carried 
out by using the TaqMan® Fast Advanced Master Mix from Applied Biosystems® 
and the TaqMan® MicroRNA assay. RNU-48 was used as an endogenous 
control in both cDNA synthesis and qPCR for normalization  
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Next, the PCR master mix to conduct q-PCR was prepared as follows: 
Table 18: qPCR reaction mix for miRNA expression analyses 
Component Volume 
TaqMan® Fast Advanced Master Mix 10.00 µL 
Nuclease-free water 7.50 µL 
TaqMan® MicroRNA assay 1.00 µL 
cDNA template 1.50 µL 
Total volume 20.00 µL 
 
All the samples were loaded in triplicates in the 96-well plate including the 
endogenous controls. No-template controls were also pipetted for verifying the 
contaminations and accuracy of the PCR. The plate was then briefly centrifuged, 
sealed with an adhesive film and loaded into the instrument. The experiment was 
set up in the ViiA™ 7 with setting up the specific parameter. 
 
2.2.3 Protein expression analysis 
2.2.3.1  Protein isolation from CFBE41o- and 16HBE14o- 
 
Protein isolation from cells was carried out using lysis buffer (50 mM Tris, 100 
mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% Na-deoxycholate) containing 
proteases inhibitor (1 mM PMSF). The culture media was removed from the plate 
and further cells were washed 2 times with PBS. Immediately, 250µL of cell lysis 
buffer was directly added to Petri plate and each well of 6 well plates. After, cells 
were incubated at 4°C for 5-10 minute and scratched with cell scrapers and 
supernatants were collected in 2 mL Eppendorf tubes. Cell supernatant was 
sonicated for 30 seconds by sonicator to release of membrane-bound proteins. 
Further, supernatant used for protein quantification or stored at -80°C.  
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2.2.3.2 Protein quantification  
 
Protein concentrations were determined with a bicinchoninic acid assay kit 
(Thermo Scientific, Dreieich, Germany). It is a biochemical assay for measuring 
the total concentration of protein in a solution which involving the reaction of 
protein with an alkaline copper in the solution. Further, BCA chelate with each 
Cu+ ion and give rise to a purple-colored product, which absorbs light at a 
wavelength of 562 nm. Bovine serum albumin (BSA) with a different 
concentration in the range of 0.003-2000mg/mL was used as a standard. Protein 
lysates were pre-diluted in 1-10 dilution. 25µL of protein sample and standards 
were pipetted in duplicated into 96 wells plate. Next 200µL of BCA kit reagent 
solution A and B (50:1) was pipetted into each well of 96 wells plate. The reaction 
was incubated at 37°C for 30 min and the absorbance was measured at 562nm 
using a microplate reader (Tecan). Exact concentrations were measured by the 
standard curve in accordance with the standards. Then the volume of protein 
samples was calculated to reach 15μg of total protein. 
 
2.2.3.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting 
 
SDS-PAGE is used to separate proteins in the samples as per their molecular 
weights by electrophoresis. Protein samples prepared for the gel electrophoresis 
by mixing 4X loading buffer at the ratio 3:1 and followed by denaturation at 95°C 
for 10 min. Gels were prepared depending upon the molecular weight of proteins. 
 
Gel preparation 
Gel Electrophoresis apparatus (Bio-Rad) used for the preparation of gels. The 
gel casting apparatus was assembled with the glass plates and spacers. 
Resolving gel Component for 2 gels: 
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Table 19: Resolving gel preparation composition 
Reagents 8% 12% 
Rotiphorese Gel 30 2.655mL 4mL 
Buffer B 3.33mL 3.33mL 
10% SDS 100µL 100µL 
Water 3.84mL 2.53mL 
10 % APS 50µL 50µL 
TEMED 10µL 10µL 
Total 10 mL 10mL 
 
All reagent mixed together with continuous stirring except the TEMED and 10 % 
APS. Prior to pouring the gel, 10% APS and TEMED were added and 
immediately poured in glass wells about 1.5 cm below the wells of the comb. 
Isopropanol was added on the top of gel solution to seal the gels to avoid oxygen 
getting in which inhibit polymerization. Further resolving gels were incubated for 
45 min for solidification. After solidification isopropanol was removed. Then the 
stacking gel solution was poured on the top of resolving gel and comb were 
inserted immediately. Again, the gel was incubated for 35-40 min for 
polymerization. 
 
Stacking gel Component for 2 gels: 
Table 20: Stacking gel preparation composition 
Reagent Quantity taken 
Rotiphorese Gel 30 655µL 
Buffer C 1mL 
10%SDS 50µL 
Water 3.285mL 
10 % APS 50µL 
TEMED 5µL 
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Total 5mL 
 
Further gels were set into the electrophoresis chamber filled with 1X running 
buffer. Proteins samples (15µg) were loaded carefully into each well of the gels 
and then 7µL of Protein ladder was loaded to compare the molecular weight of 
the proteins. Initially, gels were run at 100V until proteins reached to resolving gel 
and increased the volts up to 140V during migration through resolving gel for 1-2 
hours. After separation of proteins on the gels, separated proteins were 
transferred to a PVDF-membrane by the wet transfer method. PVDF membrane 
was activated by methanol for 1 min followed by washing with water and then 
soak in transfer buffer. Cassette was prepared by loading up the sponge, 
Whatman filter, gels and membrane (presoaked in transfer buffer) in the following 
order: 
 
 
Figure 7: Wet transfer  
 
The transfer was carried out for 90 min at 100V in transfer buffer. The cooling 
pack was used to cool down the transfer buffer during transfer. After the transfer, 
membranes were removed and blocked in blocking buffer (5% non-fat milk in 1X 
TBST solution) for 2 hours at RT on the shaker. Further, the membrane was 
incubated with primary antibodies diluted in blocking buffer for overnight at 4°C. 
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Following day, membranes were washed 4 times with 1xTBST buffer for 15 min 
and subsequently incubated with secondary HRP-conjugated antibodies diluted 
in blocking buffer for 1hr at RT. After incubation, membranes were washed 4 
times with 1x TBST for 15 min. HRP signal was detected by developing the 
membrane using ECL kit (Bio-Rad) detection reagents. 2 detection reagent 
mixed in 1:1 proportion which acts as a substrate for horseradish peroxidase 
(HRP) associated with the secondary antibody. Densitometric analysis of the 
immunoblots was calculated by image J software and value was normalized with 
β-actin. 
 
2.2.3.4  Enzyme-linked immunosorbent assay (ELISA) 
 
TGF-β is a multifunctional cytokine. It is known that most of the cytokine 
expressed in the supernatant of cells. In order to analyze the levels of TGF-β1 
and TGF- β2, supernatants were collected from 5 different passages of 
CFBE41o- and 16HBE14o- cells. The TGF-β1 and TGF-β2 levels in the 
supernatants were measured by use of the TGF-β1 and TGF-β2 DuoSet 
Development Kits (R&D Systems, USA). Initially, TGF-β1 and TGF-β2 DuoSet 
Development Kit containing reagents were diluted as follows: 
Table 21: Reagent preparation for ELISA 
Reagents TGF-β1 TGF-β2 
Capture Antibody 360 μg/mL of mouse anti-
TGF-β1 when 
reconstituted with 1 mL 
PBS 
 
360 μg/mL of mouse 
anti-TGF- β2 after 
reconstitution with 1 mL 
PBS 
Detection Antibody 54 μg/mL of biotinylated 
chicken anti-human TGF-
β1 when reconstituted 
27 μg/mL of biotinylated 
goat anti-human TGF-β2 
when reconstituted with 
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with 1mL Reagent Diluent 
 
1mL PBS 
Standard 140 ng/mL of recombinant 
human TGF-β1 when 
reconstituted with 0.5mL 
Reagent Diluent 
 
70 ng/mL of recombinant 
human TGF-β2 when 
reconstituted with 0.5 
mL 
Reagent Diluent 
Streptavidin-HRP 1.0 mL of streptavidin 
conjugated to 
horseradish-peroxidase 
 
1 mL streptavidin 
conjugated to 
horseradish-peroxidase 
 
Latent TGF-β1 and TGF-β2 activation were carried out by the addition of 3.5 µL 
HCL on 100µL supernatant samples into each microcentrifuge tube. The samples 
were vortexed and incubated for 1 hour at 4°C or on the ice. Further, the samples 
were neutralized by addition of 7µL NaOH and 9µL HEPES.  
 
Next, 100µL diluted Capture Antibody was pipetted in each well of the 96 wells 
plates and incubated overnight at 4°C. Following next day, each well was 
emptied and washed 3 times with 400µL wash buffer. 300µL block buffer was 
added to each well of the plate and incubated for 1hr at RT. Each well was 
emptied and washed 3 times with 400µL wash buffer. 100µL of Standard or 
sample or controls was added to respective wells of the plate and incubated for 
2hrs at RT. Each well was emptied and washed 3 times with 400µL wash buffer. 
Further, 100µL diluted Detection Antibody was added to each well of the plate 
and incubated for 2 hours at RT. Each well was emptied and washed 3 times 
with 400µL wash buffer. After incubation, 100µL diluted Streptavidin-HRP was 
added into each well of the plate and incubated for 20 minutes at RT in the dark. 
Each well was emptied and washed 3 times with 400µL wash buffer 100µL TMB 
substrate was added to each well of the plate and incubated for 20 minutes at RT 
in the dark. The reaction was stopped by addition of 100µL Stop Solution into 
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each well of the plate. Optimal density was measured immediately at 570nm on a 
micro-plate reader. 
 
2.2.3.5 Immunofluorescence: 
 
It is cell imaging techniques, in which antibodies are used to label a specific 
target antigen with a fluorescent dye (also called as fluorophores). A chemically 
conjugated antibody with fluorophores allows visualization of the target 
distribution proteins on or in the cells. 
 
Cells were grown and treated in BD falcon culture chamber slides. Cells were 
grown to 80–90% confluence, and further treated with TGFβ (2ng/mL) for 9hr or 
EIPA (0.1, 1.0 and 10μM) for 4hrs. After treatment, media was removed and cells 
were washed twice with PBS (Gibco). Further cells were fixed by adding 4% 
paraformaldehyde (Sigma-Aldrich) on the cells for 15 min at room temperature. 
Cells were washed 3 times with PBS for 5 min each. Cells were incubated with 
0.1% saponin (Sigma-Aldrich) for 10–15 min at room temperature for 
permeabilization. After, cells were again washed 3 times with PBS for 5 min. 
Cells were kept for blocking in 1% BSA for 30 min at room temperature, flowed 
by overnight incubation primary antibodies diluted in 1% BSA (1:200) at 4°C. The 
next day, cells were washed twice with PBS and incubated with secondary 
antibodies conjugated with appropriate fluorophores 488 or 555 (Alexa Fluor) 
diluted in 1% BSA (1:400) for 1hr at room temperature in dark. Followed by again 
PBS wash, chamber slides were detached from the glass slide, and nuclei were 
counterstained with mounting medium containing 4,6-diamidino-2-phenylindole 
(DAPI) before the mounting of the coverslip (VECTASHIELD Mounting Medium 
with DAPI). Slides were examined under Zeiss immunofluorescence microscope 
at 63X magnification. 
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2.2.4 Transfections 
2.2.4.1 Transfection of miRNA mimics and inhibitor: 
miRNA mimics and inhibitors were reverse transfected using the siPORT™ 
NeoFX™ transfection agent from Invitrogen™. Further cells were trypsinized and 
plated along with the transfection complex in 6-well culture plates. Negative 
controls each different for mimics and inhibitors were also transfected in another 
well. All the miRNA mimics, inhibitors, and negative controls were dissolved in 
the diluents provided by the manufacturer and further diluted to 10 µM working 
concentration. For negative control, a mock test was also performed in which the 
cells were treated with only the transfection reagent. Opti-MEM® I was used for 
the complex formation instead of serum-free medium. Then, in 2 Eppendorf cups 
each for miRNA inhibitor, miRNA mimic, miRNA inhibitor negative control, 
miRNA mimic negative control, and mock the components were mixed as 
follows: 
 
Table 22: Reagent composition for miRNA transfection 
 Components Control Mock miRNA 
mimic/inhibitor 
Tube A Opti-MEM® I - 47 µL 47 µL 
siPORT™ NeoFX™ - 3 µL 3 µL 
 
Tube B Construct - - 3 µL 
Opti-MEM® I - 50 µL 47 µL 
A + B mix - 100 µL 100 µL 
 Complete Medium 1,000µL 900 µL 900 µL 
Total Medium 1,000µL 1,000µL 1,000µL 
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After mixing the described components, both tubes were incubated at room 
temperature for 15 min and mixed together. The further mixture was incubated at 
room temperature for 15 min. The cells were trypsinized prior to the start of 
complex formations and were dissolved in about 1mL MEM medium. After the 
complex formation, 80,000 cells/well along with the complete medium (900 µL) 
and the complex (100 µL) were plated to respective wells. The miRNA mimic or 
inhibitor effects were measured after 72 hours by western blotting to analyze 
specific protein regulation. 
 
2.2.4.2 Transfection of TLR-4-yfp plasmid: 
 
Transfection is the process of introducing foreign DNA or RNA into the eukaryotic 
cells. There are two important ways for transfection, which is Cationic lipid-
mediated transfection and electroporation. In our experiments, lipofection was 
used as the method of transfection. It has positively charged surface, which 
interacts with negatively charged DNA and form lipid-DNA complex. Positive 
charged on liposome also allowing fusion of the liposome/nucleic acid 
transfection complex with the negatively charged cell membrane. Further, this 
transfection complex uptake is carried out by endocytosis. 
 
CFBE41o- and 16HBE14o- cells were cultured until 60–70% confluence in BD 
falcon culture chamber slides and treated with EIPA (10μM) for 4 hrs. Further 
cells were transfected using transfection reagent lipofectamine with1 μg of 
reporter plasmids of TLR-4-YFP. 2μg of TLR-4-YFP plasmid and Lipofectamine 
2000 transfection reagent (Invitrogen Carlbad CA) were incubated separately in 
Opti-MEM (Gibco, Life Technologies) for 5 min and mixed together. The mixture 
was incubated for 20 min at room temperature. The further pre-incubated mixture 
was diluted with serum and antibiotic-free DMEM medium at the ratio of 1:1 and 
added dropwise to the cells. After 4hrs of transfection, cells medium was 
replaced with DMEM supplemented with antibiotics and incubated for 24hrs. Next 
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day, cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 15 min at room 
temperature and washed twice with PBS. Mounting medium containing 4,6-
diamidino-2-phenylindole (DAPI) used for counterstained the nuclei and 
mounting the coverslip. TLR-4-yfp signals were captured in Zeiss 
immunofluorescence microscope at 63X magnification.   
 
2.2.5 Statistical analysis 
 
Data are presented as means ± SEMs and was given unless stated otherwise. 
Statistical analysis was performed using student’s unpaired t-test for comparison 
of two groups and one-way ANOVA following Bonferroni post-test was used for 
multiple comparison studies with more than two groups. Prism 5 and Image-J 
was used to analyze the statistical data.  
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3 Results 
3.1 TGF-β expression in CFBE41o- and 16HBE14o- cells 
 
The transforming growth factor beta (TGF-β) not only controls proliferation and 
cellular differentiation also acts as a multifunctional cytokine, which exhibits 
immunosuppressive capacity. 
TGF-β is elevated in bronchoalveolar lavage fluid from children with CF and in 
lung tissue sections from the CF patients [119]. Despite previously reported the 
elevated level of TGF-β in CF  [69-71], expression of TGF-β was not studied in 
delta F508 mutation in CFTR gene (CFBE41o-) and normal human bronchial 
epithelial cells (16HBE14o-). So, we were interested in analyzing TGF-β 
expression in bronchial epithelial cells with a defective deltaF508 mutation in 
CFTR gene (CFBE41o-) and normal human bronchial epithelial cells 
(16HBE14o-) cells. 
 
3.1.1 mRNA expression of TGF-β by q-PCR 
To test the TGF-β levels, we analyzed mRNA expression of TGF-β in CF and 
normal epithelial cells by q-PCR. RNA extracted from CFBE41o- and 16HBE14o- 
cells, reverse-transcribed complementary DNA (cDNA) amplified by quantitative 
real-time PCR (q-PCR). We noticed a significant downregulation of TGF-β at 
mRNA level in CFBE41o- cells (*p<0.05 and **p<0.01) compared to that of 
16HBE14o- cells (Fig. 8). 
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Figure 8: Relative mRNA expression of TGF-β in CFBE41o- vs. 16HBE14o- cells. Data 
presented are mean ± SEM and asterisks indicate statistical significance determined by 
student’s t-test (*p<0.05 and **p<0.01). The experiments were repeated three times 
(n=3). 
 
3.1.2 Protein expression of TGF-β by immunoblotting 
 
Further, we analyzed protein expression of TGF-β in cell lysate of CF and normal 
epithelial cells by immunoblotting. At the protein level, we also noticed a 
significant downregulation of TGF-β in CFBE41o- cells (*p<0.05) compared to 
16HBE14o- cells (Fig. 9A and 9B). β actin was used as loading control and 
served as the standard for densitometry analysis. 
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Figure 9: A) Representative immunoblotting for levels of TGF-β in cell lysate of 
CFBE41o- and 16HBE14o- cells. The molecular size of each protein is indicated on the 
right. (B) Densitometry analysis of immunoblotting for TGF-β. TGF-β-to-β-actin ratio was 
calculated and is represented as bar graphs. Data represent means ± SEM and 
asterisks indicate statistical significance determined by Student’s t-test (*p<0.05, 
16HBE14o- vs. CFBE41o- cells). IDV, intensity density values (n=5). 
 
3.1.3 Level of TGF-β by ELISA 
 
TGF-β is multifunction cytokine and plays an important role in regulating the 
immune system [120]. Cytokines often circulate as proteins bound to soluble 
receptors, carrier proteins, or inhibitors, which can be easy to detect by enzyme-
linked immunosorbent assay (ELISA) [121]. To analyze the level of TGF-β in 
cells media supernatant, ELISA was performed in cell culture supernatant of 
CFBE41o- and 16HBE14o- cells. Relative to mRNA expression the protein levels 
of TGF-β1 and TGF-β2 were found less expressed in the medium supernatant of 
CFBE41o- compared to 16HBE14o- cells, but the differences were not significant 
(Fig. 10). 
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Figure 10: ELISA in CFBE41o- and 16HBE14o- assessed secretion of TGF-β1 and 
TGF-β2 cells supernatant (n=5). 
 
3.1.4 Expression of TGF-β by immunofluorescence 
 
To confirm the expression of TGF-β in vitro, immunofluorescence experiments 
were performed in CFBE41o- and 16HBE14o- cells. TGF-β signals were less in 
CFBE41o- cells whereas intense signals were observed in 16HBE14o- cells 
(Fig.11). The results obtained indicate the decrease in TGF-β expression in 
CFBE41o- compared to that of 16HBE14o- cells. This further supports our 
previous results and confirmed decreased TGF-β expression in CFBE41o- cells. 
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Figure 11: Immunofluorescence analysis of TGF-β expression in CFBE41o- and 
16HBE14o- cells. Representative images from immunofluorescence were using an 
antibody against TGF-β (Dilution1: 400). Red: TGF-β positive stain, Nuclei is stained 
with DAPI (blue) (n=3), Scale bar: 10μm. 
 
3.1.5 TGF-β expression in corrCFBE41o- cells 
 
CF is caused by defective CFTR, which might be responsible for alteration of 
many genes. So, it was crucial to investigate whether defective CFTR might 
involve in downregulation of TGF-β. To confirm CFTR involvement in TGF-β 
expression immunoblotting was performed in the cell lysate of corrected (corr) 
CFBE41o- cell and compared with CFBE41o- and 16HBE14o- cells. 
(corrCFBE41o- cell line is CFBE41o-isogenic wild-type CFTR-complemented 
counterpart). 
 
As shown before TGF-β expression is reduced in CFBE41o- cells as compare to 
the normal 16HBE14o- cells. When compared TGF-β expression in CFBE41o- 
cells and corrCFBE41o- cells, it was observed that TGF-β expression was 
slightly increased in corrCFBE41o- cell as compared to CFBE41o- cells but 
differences were not significant (Fig. 12A and 12B). Corrected CFTR increased 
the expression of TGF-β protein expression, suggesting that, defective CFTR 
might be associated with downregulation of TGF-β in cystic fibrosis. Taken 
together, these results confirmed that TGF-β expression is downregulated in 
CFBE41o- as compare to 16HBE14o- cells. 
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Figure 12: A) Representative immunoblotting for levels of TGF-β in cell lysate of 
CFBE41o- and 16HBE14o- cells and corrCFBE41o- cells. β -actin was used as loading 
control. The molecular size of each protein is indicated on the right. B) Densitometry 
analysis of immunoblotting for TGF-β, relative to β-actin. CFBE41o- versus 
corrCFBE41o- cells. Data presented are mean ± SEM (*p<0.05, student’s t-test, ns-non-
significance). The experiments were repeated thrice (n=3). 
 
3.2 miRNA-16 dependent TGF-β expression 
 
Various studies have been shown that the expression of ENaC is elevated in the 
respiratory epithelial cells in cystic fibrosis [122]. One such miRNA regulating the 
ENaC expression by down-regulating TGF-β is miR-16. A Recent study reported 
that miR-16 modulates the ENaC channel through downregulation of TGF-β in 
ALI [55]. We were interested in miR-16 regulation and its effect on TGF-β 
expression in CF cells. 
 
3.2.1  miR-16 expression 
 
To determine whether the expression of miR-16 was altered in CF, quantitative 
real-time PCR (qPCR) on RNA lysates from CFBE41o- and 16HBE14o- cells 
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was performed. Results obtained showed that miR-16 was expressed similarly 
CFBE41o- and 16HBE14o- cell lines (Fig.13A).  
 
3.2.2 TGF-β expression upon miR-16 mimic and anti-miR-16 transfection in 
16HBE14o- cells and CFBE41o- cells 
 
 Although there was no elevated level of miR-16, TGF-β expression regulated by 
miR-16 was examined in CF cell lines. Therefore, to find the association between 
miR-16 and TGF-β, 16HBE14o- cells were transfected with miR-16 mimics to 
increase miR-16 expression and anti-miR-16 were transfected in CFBE41o- cells 
to block miR-16 expression. After transfection, immunoblotting was performed on 
cell lysate to analyze the TGF-β expression. β actin used as loading control and 
served as the standard for densitometry analysis. Over-expression of miR-16 led 
to a reduction of TGF-β expression 16HBE14o- cells (Fig. 13B and 13C). 
Blocking of miR-16 led to increasing of TGF-β expression in CFBE41o- cells (Fig. 
13D and 13E). Collectively, these data suggested that miR-16 play role in TGF-β 
regulation, which might contribute to developing a new therapeutic approach in 
CF. 
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Figure 13: A) Relative miR-16 expression in CFBE41o- compared 16HBE14o- cells. 
RNU-48 was used for normalization. Cells were transfected with miR-16 mimic and anti-
miR-16 for 72 hours and harvested for protein analysis. Untreated cells were taken as 
negative control. B) Representative immunoblot of TGF-β at protein levels in cell lysate 
of 16HBE14o- cells after transfection of mimic miR-16. β-actin was used as loading 
control. The size of each band is indicated on the right. C) Densitometry analysis of 
immunoblot for TGF-β, *p<0.05, student’s t-test, Trasfected16HBE14o- vs. non-
transfected 16HBE14o- cells. Data are presented as mean ± SEM (n=5). D) 
Representative immunoblot of TGF-β at protein levels in cell lysate of CFBE41o- cells 
after transfection of anti-miR-16. β-actin was used as loading control. The molecular size 
of each protein is indicated on the right. E) Densitometry analysis of immunoblot for 
TGF-β, Transfected CFBE41o- vs. non-transfected CFBE41o- cells(n=1). 
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3.3 Hypoxia stabilization associated TGF-β expression  
We have previously demonstrated that altered iron homeostasis leads to hypoxia 
in cystic fibrosis [107]. This leads to HIF-1α destabilization in cystic fibrosis. 
Previous studies reported by other groups suggest that the hypoxia increases the 
expression of TGF-β, which is regulated by its transcription factor, hypoxia 
response element (HRE) [123]. To confirm, impaired HIF-1α in CF might be 
responsible for TGF-β downregulation, the expression of TGF-β under hypoxic 
condition (0.1% O2) to stabilize the HIF-1α in CFBE41o- and 16HBE14o- cells 
was analyzed. The immunoblotting analysis revealed a two-fold increase of TGF-
β in 16HBE14o- cells. On the contrary, TGF-β expression was reduced in 
CFBE41o- under hypoxia (Fig. 14A and 14B). This might be due to HIF-1α 
destabilization in CF cells since oxygen deprivation might also increase free 
radicals, damage DNA, and causes cell death [124].   
   
Since hypoxic condition seems to fail in the stabilization of HIF-1α and showed 
reduced TGF-β expression in CFBE41o- cells. To analyze this hypothesis a 
known hypoxia mimic agent Deferoxamine (DFO) was used. Deferoxamine is a 
hypoxia-mimetic agent which artificially induces hypoxia by blocking the 
degradation of HIF-1α [125]. CFBE41o- and 16HBE14o- cells were treated with 
100 μM/mL of deferoxamine (DFO) for 30 minutes, 1, 2 and 4 hours).  
 
Results obtained from immunoblotting revealed a time-dependent increase in 
TGF-β expression upon DFO in CFBE41o- and 16HBE14o- lines (Fig. 14C). 
Densitometry analysis of 3 biological repeats also showed slight increased TGF-
β expression in CFBE41o- and no significant difference in 16HBE14o- cells (Fig. 
14D). Hence, hypoxia in CFBE41o- cells might be responsible for downregulation 
of TGF-β. 
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Figure 14: A) Representative immunoblot for levels of TGF-β in cell lysate of hypoxic 
condition (0.1% O2) for 24 hours in CFBE41o- and 16HBE14o- cells. β -actin was used 
as loading control. The molecular size of each protein is indicated on the right. B) 
Densitometry analysis of immunoblotting for TGF-β, Normoxic condition served as a 
control of each cell line. Normoxic conditions were compared with the hypoxic condition 
in both 16HBE14o- and CFBE41o- cells. C) Representative immunoblotting for levels of 
TGF-β in cell lysate of DFO (100mM) at 30 minutes, 1, 2 and 4 hours. in CFBE41o- and 
16HBE14o- cells. β -actin was used as loading control. The molecular size of each 
protein is indicated on the right. D) Densitometry analysis of immunoblotting for TGF-β, 
non-treated cells served as a control of each cell line. 16HBE14o- vs. CFBE41o- cells. 
Data are presented as mean ± SEM. The experiments were repeated 3 times (n=3). 
 
 
3.4 Decreased expression of ferroportin in CF 
 
Turi et al. 2008 showed that overexpression of ENaC leads to the higher import 
of Na+ ions and subsequent iron bypass into the cells thereby increasing the iron 
concentration [105]. This supports the published studies in Chillappagari et al. 
regarding the increased iron concentration and hypoxia in Cystic fibrosis [107]. It 
is known that ferroportin is an iron exporter, which up-regulate in the presence of 
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excess intracellular iron levels and involved in iron detoxification in the lung. To 
confirm the Ferroportin regulation in CF, Expression of ferroportin was analyzed 
in CFBE41o- and 16HBE14o- cells. 
 
3.4.1 mRNA expression of ferroportin by q-PCR 
 
Ferroportin levels were studied by analyzing mRNA expression of ferroportin in 
CFBE41o- and 16HBE14o- cells by using q-PCR. cDNA was synthesized from 
RNA extracted from CFBE41o- and 16HBE14o- cells and amplified by q-PCR. q-
PCR results showed a significant downregulation of TGF-β at mRNA level in 
CFBE41o- cells (*p<0.05 and **p<0.01) compared to that of 16HBE14o- cells 
(Fig. 15) 
 
Figure 15: Relative mRNA expression of Ferroportin in CFBE41o- compared 
16HBE14o- cells. Data presented are mean ± SEM and asterisks indicate statistical 
significance determined by student’s t-test (*p<0.05 and **p<0.01). The experiments 
were repeated 3 times (n=3). 
 
3.4.2 Protein expression of ferroportin by western blot 
 
Further, protein expression of ferroportin was analyzed in cell lysate of 
CFBE41o- and 16HBE14o- by using immunoblotting. At the protein level, a 
significant downregulation of ferroportin was observed in CFBE41o- cells 
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(*p<0.05) compared to 16HBE14o- cells (Fig. 16A and 16B), β actin used as 
loading control and served as the standard for densitometry analysis. 
 
 
Figure 16: A) Representative immunoblot for expression of ferroportin in cell lysate of 
CFBE41o- and 16HBE14o- cells. The size of each band is indicated on the right. B) 
Densitometry analysis of immunoblotting for ferroportin. Data represent means ± SEM 
and asterisks indicate statistical significance determined by Student’s t-test (*p<0.05, 
16HBE14o- vs. CFBE41o- cells). The experiments were repeated 5 times (n=5). 
 
3.4.3 Expression of ferroportin by immunofluorescence 
 
To confirm the expression of ferroportin in vitro, immunofluorescence 
experiments were performed in CFBE41o- and 16HBE14o- cells. Ferroportin 
signals were reduced in CFBE41o- cells whereas intense signals were detected 
in 16HBE14o- cells (Fig.17). The results obtained indicate the decrease of 
ferroportin expression in CFBE41o- as compared to that of 16HBE14o- cells. 
This further confirmed the decreased ferroportin expression in CFBE41o- cells. 
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Figure 17: Immunofluorescence analysis of ferroportin expression in CFBE41o- and 
16HBE14o- cells. Representative images from immunofluorescence were using an 
antibody against ferroportin (Dilution1:400). Red: TGF-β positive stain, nuclei are stained 
with DAPI (blue). The experiments were repeated 3 times (n= 3), Scale bar: 10μm. 
 
3.4.4 Ferroportin expression in corrCFBE41o-  cells 
 
To verify the decrease of ferroportin in CFBE41o- cells, we analyzed the 
ferroportin expression in corrCFBE41o-  cell line and compared with CFBE41o- 
and 16HBE14o- cells. Previous results showed that ferroportin expression is 
reduced in CFBE41o- cells as compared to that of normal 16HBE14o- cells. 
Further, comparative study of ferroportin expression in CFBE41o- cells and 
corrCFBE41o- cells revealed that ferroportin expression was significantly 
increased in corrCFBE41o- cell than CFBE41o- cells (Fig. 18A and 18B). 
Therefore, defective CFTR might also be associated with downregulation of 
ferroportin in CF.              
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Figure 18: A) Representative immunoblot for expression of ferroportin in cell lysate of 
CFBE41o- and 16HBE14o- cells and corrCFBE41o- cells. The molecular size of each 
protein is indicated on the right. B) Densitometry analysis of immunoblot for ferroportin, 
relative to β-actin. CFBE41o- vs. corrCFBE41o-cells. Data presented are mean ± SEM 
(*p<0.05, student’s t–test, ns-non-significance). The experiments were repeated 3 times 
(n=3). 
 
3.5 Hypoxia stabilization associated ferroportin expression 
 
Since the ferroportin promoter contains HIF-Responsive Elements (HRE) in the 
promoter. Additionally, hypoxia in CF might be involved in regulation of 
ferroportin expression in CF cells[116]. Therefore, ferroportin expression was 
analyzed under the hypoxic condition and hypoxia mimetic agent by 
immunoblotting in CFBE41o- and 16HBE14o- cells. To create a hypoxic 
condition, both cell lines were incubated at 0.1% O2 for 24hrs and cell lysates 
were collected immediately after the incubation. Further, protein expression of 
ferroportin by immunoblotting revealed, an up-regulation of ferroportin under 
hypoxic condition compared to that of the normoxic condition in both CFBE41o- 
and 16HBE14o- cells (Fig. 19A and 19C). To confirm these finding, the cells 
were treated with known hypoxia mimic agent deferoxamine (DFO). Cells were 
treated with 100mM of DFO for30 minutes, 1, 2 and 4 hours. Immunoblotting was 
performed on cell lysate of treated cells to analyze the ferroportin expression. 
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Results showed that significant time-dependent increase of ferroportin 
expression (*p<0.05) in CFBE41o- whereas ferroportin expression remains 
unchanged in 16HBE14o- cells (Fig. 19B and 19D). These results conclude that 
stabilization of HIF-1α led to increased ferroportin expression in CF epithelial 
cells.  
 
 
Figure 19: A) Representative immunoblot for levels of ferroportin in cell lysate of hypoxic 
condition (0.1% O2) for 24 hours in CFBE41o- and 16HBE14o- cells. β -actin was used 
as loading control. The molecular size of each protein is indicated on the right. B) 
Representative immunoblotting for levels of ferroportin in cell lysate of DFO (100mM) for 
increased time (30’ 1, 2 and 4 hours) in CFBE41o- and 16HBE14o- cells. β-actin was 
used as loading control. C) Densitometry analysis of immunoblot for TGF-β, Normoxic 
condition of cells served as a control of each cell line. Normoxic conditions were 
compared with hypoxia condition in both 16HBE14o- and CFBE41o- cells. D) 
Densitometry analysis of immunoblot for ferroportin, non-treated cells served as a 
control of each cell line. 16HBE14o- vs. CFBE41o- cells. Data are presented mean ± 
SEM, *p<0.05, student’s t-test. The experiments were repeated 3 times (n=3). 
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3.6 Effect of TGF-β treatment on expression of ferroportin expression 
 
The previous result on TGF-β expression in CF cell lines led to a hypothesis that 
reduced TGF-β might be associated with ferroportin expression.  
To verify the effect of TGF-β in ferroportin expression, we analyzed ferroportin 
protein expression by immunoblotting and immunofluorescence in both 
CFBE41o- and 16HBE14o- cells under TGF-β treatment.  
 
Cells were stimulated with increasing concentration of TGF-β (0,2,5,10 20ng/mL) 
for 9 hours and 2ng/mL TGF-β was treated for different time points (0, 3, 6, 9 
hours). Studies with increasing concentration of TGF-β showed an up-regulation 
of ferroportin expression until 10ng in both CFBE41o- and 16HBE14o- cells (Fig. 
20A and 20C) and time-dependent studies also revealed, an up-regulation of 
ferroportin expression in CFBE41o- but no effect on 16HBE14o- cells (Fig. 20B 
and 20D). 
 
Immunofluorescence was performed in vitro to confirm the ferroportin surface 
expression. Cells were treated with TGF-β (2ng) for 9hrs and further stained with 
ferroportin antibody. Obtained results also confirmed prominent staining of 
ferroportin in stimulated compared to that of none- stimulated CFBE41o- cells. 
No much difference was observed in 16HBE14o- cells (Fig. 20E). 
 
Exogenous stimulation with TGF-β on CFBE41o- cells resulted in enhanced 
expression of ferroportin, which might be associated with maintaining iron 
homeostasis in CF. 
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Figure 20: A) Representative immunoblot for detection of ferroportin in cell lysate of 
CFBE41o- and 16HBE14o- cells upon TGF-β treatment for indicated time interval (A) 
and concentration (B). β-actin was used as loading control. The molecular size of each 
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protein is indicated on the right. C) Densitometry analysis of ferroportin immunoblotting 
upon time and concentration (D) dependent treatment of TGF-β. TLR-4-to-β-actin ratio 
was calculated and represented as bar graphs. Data represent means ± SEM, and 
asterisks indicate statistical significance determined by Student’s t-test (*P<0.05). 
Significance was calculated and is relative to respective time points for each cell line. 
IDV, intensity density values. The experiments were repeated 3 times. E) Ferroportin 
staining (red) using immunofluorescence in CFBE41o- and 16HBE14o- cell lines upon 
TGF-β (2ng/mL) stimulation for 9 hours The experiments were repeated 3 times (n=3). 
Non-treated cells served as control. Nuclei stained with DAPI (blue). 
 
3.7 Effect of TGF-β treatment on expression of TLR-4 expression 
 
TGF-β is known to act as ENaC channel inhibitor. Therefore, it might reduce 
ENaC mediated iron concentration in the cells. Further, this can stabilize the HIF-
1α and subsequently can enhance TLR4 expression [114]. Therefore, TLR-4 
expression was investigated upon external application of TGF-β on CFBE41o- 
and 16HBE14o- cells. Immunoblot and immunofluorescence were performed to 
analyze TLR-4 expression upon TGF-β treatment. Cells were stimulated with 
TGF-β in dose-dependent manner (0,2,5,10 20ng/mL) for 9 hours and time-
dependent manner (0, 3, 6, 9 hours) of 2ng/mL TGF-β. 
 
Immunoblot analysis in both time (Fig. 21A and 21C) and dose dependent (Fig. 
21C and 21D) manner showed a slight increase in TLR-4 expression upon TGF-
β treatment in both CFBE41o- and 16HBE14o- cells. β-actin used as loading 
control and served as the standard for densitometry analysis. 
 
In vitro immunofluorescence was performed to confirm the TLR-4 surface 
expression. Cells were treated with TGF-β (2ng) for 9hrs and further stained with 
TLR-4 antibody. Obtained results also confirmed prominent staining of TLR-4 in 
stimulated compared to that of non-stimulated CFBE41o- and 16HBE14o- cells 
(Fig. 21E). 
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These results concluded that exogenous treatment with TGF-β on CFBE41o- 
cells result in enhanced expression TLR-4 surface expression in CF epithelial 
cells. 
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Figure 21: A) Representative immunoblot for detection of TLR-4 in cell lysate of 
CFBE41o- and 16HBE14o- cells upon TGF-β treatment for indicated time interval (A) 
and concentration (B). β -actin was used as loading control. The molecular size of each 
protein is indicated on the right. C) and D) Densitometry analysis of TLR-4 
immunoblotting upon time and concentration dependent treatment of TGF-β. TLR-4 to β-
actin ratio was calculated and represented as bar graphs. Data represent means ± SEM, 
and asterisks indicate statistical significance determined by Student’s t-test (*P<0.05). 
Significance was calculated and is relative to respective time points for each cell line. 
IDV, intensity density values. The experiments were repeated 3 times (n=3). E) TLR-4 
staining (green) using immunofluorescence in CFBE41o- and 16HBE14o- cell lines upon 
TGF-β (2ng/mL) stimulation for 9 hours. The experiments were repeated 3 times (n=3). 
Non-treated cells served as control. Nuclei are stained with DAPI (blue). 
 
3.8 ENaC- channel inhibition by amiloride upregulates the expression of 
Ferroportin. 
 
Previous literature showed that overexpression of ENaC associated with high 
intracellular Na+, subsequently leading to increased iron concentration. 
The effect of ENaC channel inhibitor, EIPA [5-(N-Ethyl-N-isopropyl) amiloride] 
on ferroportin expression was investigated on CFBE41o- and 16HBE14o- cells. 
Therefore, CFBE41o- and 16HBE14o- cells were treated with increasing 
concentration of EIPA (0, 0.1,1.0,10 mM) for 4hrs. Ferroportin expression was 
investigated by immunoblot and immunofluorescence. Immunoblot analysis 
revealed, a concentration-dependent increase of ferroportin expression upon 
EIPA treatment in both CFBE41o- and 16HBE14o- cells with no significant 
differences (Fig. 22A and 22B). Immunofluorescence results also confirmed the 
increase of ferroportin staining upon increasing concentration of EIPA in both 
CFBE41o- and 16HBE14o- cells (Fig. 22C). 
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Collectively, these findings demonstrate that ENaC channel inhibition up-
regulates ferroportin expression which might further assist to reduced iron 
overload in CF. 
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Figure 22: A) Representative immunoblotting for detection of ferroportin in cell lysate of 
CFBE41o- and 16HBE14o- cells upon EIPA treatment for concentration. β-actin was 
used as loading control. The molecular size of each protein is indicated on the right B) 
Densitometry analysis of ferroportin immunoblotting upon increasing concentration of 
EIPA. Ferroportin-to- β-actin ratio was calculated and is represented as bar graphs. 
Data represent means ± SEM. IDV, intensity density values. C) Ferroportin staining 
(red) using immunofluorescence in CFBE41o- and 16HBE14o- cell lines upon EIPA 
stimulation for 4 hours. The experiments were repeated 2 times (n=2). Untreated cells 
served as control. Nuclei stained with DAPI (blue). 
 
3.9 ENaC channel inhibition by amiloride restores TLR-4 expression in 
CFBE cell lines 
 
ENaC channel inhibition associated ferroportin upregulation and reduced iron 
intake in the epithelial cells might lead to decrease intracellular iron 
concentration. Further, can cause HIF-1α stabilization and might influence on 
TLR-4 expression in CF epithelial cells. Previously Kim et al. showed that HIF-1α 
augments the TLR-4 expression. So TLR-4 expression upon ENaC inhibition was 
inspected. 
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Cells were treated with increasing concentration of EIPA (0, 0.1,1.0,10 mM) for 4 
hours. Immunoblot and immunofluorescence studies were performed to analyze 
the TLR-4 expression. Results obtained from immunoblot analysis did not show 
much difference in TLR-4 protein expression upon EIPA treatment in both 
CFBE41o- and 16HBE14o- cells (Fig. 23A and 23B). Interestingly, 
immunofluorescence staining showed intact and punctate staining of TLR-4 on 
the surface in increasing concentration of EIPA in CFBE41o- and 16HBE14o- 
cells (Fig. 23C). 
 
Therefore, these results provide evidence that ENaC inhibition improved the 
TLR-4 surface expression in Cystic fibrosis epithelial cells. 
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Figure 23: A) Representative immunoblot for detection of TLR-4 in cell lysate of 
CFBE41o- and 16HBE14o- cells upon treatment with increasing concentration of EIPA. 
β -actin was used as loading control. B) Densitometry analysis of TLR-4 immunoblotting 
upon increasing concentration of EIPA. TLR-4 to β-actin ratio was calculated and is 
represented as bar graphs. Data are representing means ± SEM and asterisks indicate 
statistical significance determined by Student’s t-test (*P<0.05). Significance was 
calculated and is relative to respective time points for each cell line. IDV-intensity 
density values. C) TLR-4 staining (green) using immunofluorescence in CFBE41o- and 
16HBE14o- cell lines upon EIPA stimulation for 4 hours. The experiments were 
repeated 2 times (n=2). Untreated cells served as control. Nuclei stained with DAPI 
(blue). 
 
3.9.1 Transfection of TLR-4-yfp to CFBE41o- and 16HBE14o- cells 
 
To support the previous finding, the impact of ENaC inhibition on TLR-4 surface 
expression, cells were transfected with TLR-4-yfp plasmid by lipofectamine to 
overexpress the TLR-4 in the cells. After transfection, cells were treated with 
EIPA (10μM/mL) for 4 hours. Nuclei were stained with DAPI and TLR-4-yfp 
signals were captured.  
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Observed results clearly indicated, restored TLR-4 expression upon EIPA 
treatment when compared with untreated CFBE41o- and 16HBE14o- cells (Fig. 
24A). These further confirmed ENaC inhibition result in improve TLR-4 surface 
expression in CFBE41o- cells. Collectively, these findings demonstrate that 
ENaC channel inhibition up-regulated ferroportin and improved TLR-4 surface 
expression in CF epithelial cells. 
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Figure 24: A) TLR-4 staining (green) using fluorescence microscope in CFBE41o- and 
16HBE14o- cell lines upon TLR-4-yfp transfection (24 hours) followed by EIPA 
treatment for 4 hours. Non-treated cells served as control. Nuclei stained with DAPI 
(blue). B) Same images captured in white light to focus on the TLR-4 signals. 
 
3.10 TLR-4 expression upon DFO, TGF- β and EIPA treatments 
 
Finally, to prove the hypothesis, CFBE41o- and 16HBE14o- cells were treated 
with DFO, TGF- β and EIPA treatment for 5 hours and TLR-4 protein expression 
was analyzed by immunoblotting. This study confirmed the increase of TLR-4 
expression in both cells lines (Fig. 25A and 25B). Therefore, DFO, TGF- β and 
EIPA increased TLR-4 expression through HIF-1α stabilization, which might be 
due to reduced iron concentration in the cell. 
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Figure 25: A) Representative immunoblot for detection of TLR-4 in cell lysate of 
CFBE41o- and 16HBE14o- cells upon DFO, TGF- β and EIPA. β-actin was used as 
loading control. B) Densitometry analysis of TLR-4 immunoblotting upon increasing 
concentration of EIPA. TLR-4-to- β-actin ratio was calculated and is represented as a 
bar graph. IDV, intensity density values. 
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4 Discussion 
 
In CF, the ∆F508-CFTR mutation causes defective CFTR channels, which leads 
to defective chloride ion export from the airway epithelial cells. CFTR not only 
functions as chloride channel but also regulates the epithelial sodium channel 
(ENaC) [6]. Mutation of CFTR leads to imbalances in CFTR-mediated anion 
secretion and ENaC-mediated Na+ absorption in airways epithelium and leads to 
dehydration of airway surface liquid level causing thickening of mucus secretion. 
This leads to reduced mucociliary clearance [126]. Further, it contributes to the 
bacterial infection of CF airways. Since CF airways fail to eradicate bacterial 
infection, it results in altered immune responses that lead to chronic colonization 
of CF airways by pathogens such as P. aeruginosa [32]. Along with defective 
TLR-4 surface expression, altered iron homeostasis and destabilization of 
hypoxia-inducible factor (HIF) was reported in CF airways [107]. ENaC channel is 
regulated via extrinsic and intrinsic factors including miR-16 and TGF-β and 
associated with iron uptake in airway epithelial cells [45, 54, 55].  
 
In the current study, we have shown in vitro a reduced TGF-β expression in CF 
airway epithelial cells (CFBE41o-) compared to normal human bronchial 
epithelial cells (16HBE14o-). We have also demonstrated that hypoxia, defective 
CFTR, and miR-16 in CF might lead to decrease TGF-β expression. We also 
found decreased expression of iron exporter ferroportin in CF, which seem to be 
dependent on the stability of HIF-1α. We further demonstrated that external 
application of TGF-β in CFBE41o-cells leads to increase levels of Ferroportin and 
rescue the TLR-4 surface expression in CF cells. Direct blocking of ENaC 
channel by ENaC inhibitor leads to increase the iron exporter ferroportin and 
further improve the TLR-4 surface expression in CF cells. 
 
Previous studies have shown that TLR-4 surface expression is reduced in CF 
airway epithelial cells (CFBE41o- and IB-3), leading to a reduced MyD88-related 
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and Toll/IL-1 receptor domain-containing adaptor inducing IFN (TRIF)-related 
activation of IL-6/IL-8 and type I interferon’s /interferon -inducible protein-10 [30, 
37]. However, the principal mechanisms behind reduced TLR-4 surface 
expression are still unknown. We showed that reduced TLR-4 surface expression 
leads to altered iron homeostasis, which further affects the stability of the HIF-1α 
through downregulation of hemeoxygenase-1 [107]. This might be the reason for 
an ineffective anti-inflammatory and antioxidant responses in CF, which might be 
associated with exaggerated airway inflammation in CF. 
 
Therefore, we aimed to determine the influence of ENaC mediated regulation of 
TLR-4 surface expression and factors associated with ENaC channel regulation 
including TGF-β, miR-16 and iron-related protein (FPN). 
 
To confirm our hypothesis, we used an immortalized CFBE41o-cell line, 
homozygous for the deltaF508 CFTR mutation and its corrected corrCFBE41o-
cell line with a stable expression of the wild-type CFTR protein and normal 
human bronchial epithelial cells 16HBE14o-cells. Firstly, we analyzed the 
Expression of TGF-β, which is a potent inhibitor of ENaC channels and its 
regulating factors such as miR-16 and hypoxia. 
 
4.1 TGF-β expression is reduced in CF 
 
TGF-β is expressed in lungs respiratory epithelial cells and play a crucial role in 
cellular differentiation, lung development and homeostasis [127]. It is involved in 
chronic pulmonary diseases including pulmonary fibrosis and CF [71]. Previous 
data suggested that TGF-β plays role in downregulation of CFTR channels in CF 
[72]. However, most of the studies demonstrate up-regulation of TGF-β levels in 
CF. TGF-β levels in plasma from CF patients were found to be elevated 
compared to controls [69]. TGF-β levels were increased in bronchoalveolar 
lavage fluid (BAL) from children with CF and it was shown to be associated with 
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neutrophilic inflammation with reduced lung function [70]. Further, TGF-β 
signaling was increased in lung tissue sections from CF patients [71]. While 
some studies show high TGF-β levels in CF patients there is no evidence 
emphasizing on the adverse effects of high TGF- β1 levels in CF so far [128]. In 
in vitro studies, Kelly et al. have postulated that SMAD3 levels are decreased in 
CF epithelial cells. As SMAD3 is a critical player in the TGF-β signaling pathway, 
they suggest decreased TGF-β levels in the CF cells [129]. This might be a 
reason for the controversial finding of in vivo versus in vitro studies since the 
expression of TGF-β has not been studied in delta F508 mutation in CFTR gene 
(CFBE41o-) and normal human bronchial epithelial (16HBE14o-) cells. 
 
Our results show reduced TGF-β expression in CFBE41o- cells as compared to 
16HBE14o- cells. Many studies show up-regulation of ENaC channels in CF. 
This might be the reason for TGF-β downregulation. TGF-β is also known as 
crucial ENaC channel blocker and has been shown to inhibit the epithelial 
sodium channels (ENaC) channel in acute lung injury [54, 55, 73]. It is also 
shown that TGF-β1 might impede sodium reabsorption by a downregulation of 
prostasin expression and subsequent inhibition of ENaC activity in renal epithelial 
cells [130]. Our result indicates that reduced expression of TGF-β might be 
associated with ENaC regulation in CF, which might be interesting for further 
studies. Normal expression of TGF-β in CF airways might lead to a decrease of 
Na+ reabsorption by inhibiting the ENaC activity, which further reduces the iron 
bypass through ENaC channels. Altered TGF activity could be related to 
transcription, secretion, or processing in CF, which needs to be further 
investigated for the exact mechanism for TGF-β regulation. This might help in 
understanding the pathophysiology of CF and possibility of new therapeutic 
options for CF treatment. 
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4.2 miR-16 downregulate TGF-β expression in CF cells 
 
MicroRNAs (miRNAs) are small nucleotide sequences for negative regulation of 
various genes and numerous biological processes. 
In CF, mutation of CFTR leads to imbalances in CFTR-mediated anion secretion 
and ENaC-mediated Na+ absorption in airways epithelium and leads to 
dehydration of airway surface causing thickening of mucus secretion, which is 
associated with chronic bacterial infection. Previous studies have shown that 
miR-16 lead to increased ENaC expression and associated with a significant 
decrease in TGF-β levels. Therefore, miR-16 related dysregulation of ENaC 
expression is mediated through downregulation of TGF-β in acute lung injury 
(ALI) [55]. To determine whether miR-16 affects the TGF-β, we analyzed TGF-β 
expression in miR-16 overexpressed normal human bronchial cells and blocked 
miR-16 in CF bronchial epithelial cells.  
 
Our study shows decreased TGF-β expression upon miR-16 overexpression and 
increased TGF-β upon blockage of miR-16 expression. Results indicate the role 
of miR-16 in downregulation of TGF-β in CF, which might further be associated 
with ENaC overexpression in CF. However, the level of miR-16 was not changed 
in CF airways cells as compare to normal bronchial airways cells (Fig. 3A).  
In future, inhibition of miR-16 by anti-miR might provide a therapeutic strategy to 
reduce ENaC overexpression though TGF-β up-regulation and might serve as a 
therapeutic agent to treat CF. 
 
4.3 Hypoxia regulates the TGF-β expression 
 
Chronic bacterial infections and altered immune responses result in reduced ASL 
which leads to thickened mucus secretion on airways lining. Furthermore, this 
causes difficulty in gas exchange in the CF lungs. Due to chronic infection, iron-
mediated reactive oxygen species are increased which alters the 
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microenvironment of the airway epithelial cells. It gives rise to low partial 
pressure of oxygen inside the lungs and subsequently induces hypoxia [108, 
109]. It was shown that defective TLR-4 and altered iron homeostasis leads to 
hypoxic response (low HIF-1α) in CF [107]. We hypothesized that hypoxia might 
be associated with reduced TGF-β expression in CF cells. So, we incubated the 
cells at hypoxia conditions to elicit a stronger hypoxic response in CF. Previous 
studies also reported that hypoxia increases the expression of TGF-β, which 
contains hypoxia response element (HRE) in promoter [123].  
 
Under hypoxia, TGF-β expression was increased in 16HBE14o- cells. Contrast to 
this TGF-β expression was decreased in CFBE41o- cells. This might be the 
effect of HIF-1α destabilization in CF cells. Oxygen deprivation might also 
increase free radicals, damage DNA, and cause cell death [124]. The hypoxic 
condition seems to fail in the stabilization of HIF-1α and showed reduced TGF-β 
expression in CFBE41o- cells. 
  
HIF activity is dependent on HIF-1α stabilization and negatively regulated by 
prolyl hydroxylase domain (PHD) enzymes. PHD residues of HIF-1α in the 
presence of O2, Fe2+, and 2-oxoglutarate further lead to polyubiquitination and 
proteasomal degradation of HIF. Fe2+ is known to play important role in 
regulating the activity of PHD. Iron chelation (or substituting Fe2+ with other metal 
ions such as CO2, Ni, and Mn) leads to diminishing the activity of PHDs [131]. 
Thus, we hypothesized that excess intracellular iron and HIF-1 destabilization in 
CF might be linked with TGF-β expression. We tested our hypothesis by a known 
hypoxia mimic agent deferoxamine (DFO). As DFO act as the hypoxia-mimicking 
agent through iron chelation, we believe that DFO chelate the excess iron and 
stabilize the HIF-1α and increases the TGF-β expression. 
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4.4 Ferroportin expression is reduced in CF and regulated by hypoxia 
 
It has been speculated that increased intracellular iron concentration could be the 
effect of ENaC overexpression and reduced hemeoxygenase-1 (HO-1) leading to 
altered iron homeostasis in CF [105, 107]. 
 
Therefore, we were interested in iron regulatory proteins such as ferroportin. It is 
a single known iron exporter in the cells and is regulated by iron regulatory 
hormone hepcidin [132]. Ferroportin is essential for regulation of iron 
homeostasis and involved in iron detoxification by up-regulating in the presence 
of excessive intracellular iron levels. Ferroportin is shown to be up-regulated in 
lung tissue from CF patients [118]. Expression of ferroportin has not been studied 
in CF airway epithelial cells. 
 
Despite increased intracellular iron in CF, we observed the downregulation of 
mRNA and proteins levels of ferroportin in the CFBE cells, which might be 
responsible for the increased iron concentration in CF epithelial cells. It is already 
known that ferroportin-deficient animals show accumulation of iron in 
enterocytes, macrophages, and hepatocytes [133]. 
 
A possible explanation for the observed reduced expression of ferroportin in CF 
airway epithelial cells might be a chronic bacterial infection and associated 
inflammation in CF. Previous studies have suggested that inflammation might 
play a role in the transcription of ferroportin [116]. Lipopolysaccharide (LPS) is 
inflammatory signals which are known to downregulate ferroportin mRNA and 
upregulate hepcidin mRNA in macrophages, leading to the cooperative 
suppression of ferroportinFerroportin protein. Bacterial-produced LPS injected 
into mice or rats are associated with decreased ferroportin expression in spleen 
and intestine [134]. 
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Ferroportin contains HIF-responsive elements (HRE) in promoter [116]. So, 
increased intracellular iron associated hypoxia in CF [107] could be another 
reason for reduced ferroportin expression in CF airways cells. 
 
Deletion of HIF-2α in Hamp−/− mice causes decreased mRNA levels 
of DMT1 and ferroportin in the intestine, which demonstrates the significance of 
HIF in the regulation of ferroportin [135]. Several studies have suggested that 
increased HIF-1α activity causes increased ferroportin levels, suppression of 
hepcidin, and increased serum iron availability [136]. Our immunoblotting results 
also show increased ferroportin expression under hypoxic conditions (1% O2). A 
similar strategy employed by using iron chelators (desferroxamine, DFO) to 
inhibit Fe2+-dependent PHD activation and HIF-1α stabilization. In our 
investigation, after DFO treatment, we found an increased ferroportin expression 
in CF compared to normal condition.  
 
Thus, we speculate that destabilization of HIF-1α in CF is not only related to 
reduced TGF-β expression but also involved in downregulation of ferroportin. 
 
4.5 Exogenous TGF-β upregulates the ferroportin and TLR-4 expression 
 
Previous results on TGF-β expression in CF cell lines led us to speculate that 
reduced TGF-β might be associated with ferroportin expression since TGF-β and 
Ferroportin both contain hypoxia response element in the promoter. It was also 
shown in astrocytes that TGF-β1 promoted iron efflux and increased the 
expression of ferroportin [137]. We analyzed whether exogenous treatment with 
TGF-β affects ferroportin in CFBE41o- and 16HBE14o- cells. Our research 
showed that ferroportin expression was increased upon TGF-β treatment. TGF-β 
mediated HIF-1α stabilization could be responsible for increased ferroportin in CF 
cells.  
 
 
92 
 
DISCUSSION 
 
  
Recently, transforming growth factor-β1 (TGF-β1) has emerged as an agonist, 
which induces HIF-1α accumulation in various cell lines including human HT1080 
fibrosarcomas and vascular smooth muscle cells under normoxic conditions [138, 
139]. However, the mechanism underlying how TGF-β1 stabilizes HIF-1α 
remains unclear. 
 
McMahon et al. showed that TGF-β decreased the transcription of PHD2 gene by 
the activation of SMAD proteins. It was also shown that SMAD signaling pathway 
plays an important role to the TGF-β since inhibition of SMAD led to the 
restoration of PHD2 mRNA and protein levels and impaired HIF-1α protein 
accumulation in response to the growth factor in HepG2 and HT1080 cells [140]. 
 
Based on earlier evidence and our in vitro results of HIF-1α stabilization by 
hypoxia (1% O2) and DFO leading to increased ferroportin expression, it can be 
speculated that exogenous application of TGF-β might increase the ferroportin 
expression. This might lead to maintain the iron homeostasis by reducing the 
intracellular iron in CF cells. 
 
In the present study, TGF-β was applied to CFBE41o- and 16HBE14o- cells. 
According to previously reported data, we suppose that sodium transport 
machinery was most likely targeted by TGF-β. External treatments of TGF-β (10 
ng/mL) can down-regulate the gene encoding αENaC (SCNN1A) in alveolar 
epithelial cells [73]. TGF-β is known to inhibit the ENaC channel in acute lung 
injury [54, 55, 73]. Inhibition of ENaC might lead to a reduction of sodium intake 
in the epithelial cells. Turi et al. demonstrated that intracellular iron accumulation 
is increased in the presence of augmented extracellular Na+. Furthermore, it was 
shown that inhibition of Na+ channels leads to lack of iron accumulation in the 
cells [105]. 
 
In CF cells, exogenous application of TGF-β can also act as ENaC inhibitor and 
might lead to reducing ENaC mediated iron bypass to maintain the iron 
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homeostasis. Due to reduced iron intake in the cells, the intracellular 
concentration of iron might be reduced. Further, reduced iron intake might 
stabilize the HIF-1α, by degradation of prolyl hydroxylase (PHD). This might be 
responsible for increased ferroportin expression in CF cells. 
 
Recent data from our lab demonstrated that defective TLR-4 in CF might 
contribute to decreased HIF-1α under normoxia and vice versa under hypoxia 
[107]. So we were interested to find out the effect of exogenous treatment of 
TGF-β on TLR-4 expression. In our investigation, we observed increment of TLR-
4 protein expression upon both times as well as concentration-dependent 
treatment of TGF-β. These results suggest that HIF-1α stabilization by TGF-β 
treatment enhances the TLR-4 expression. Our immunofluorescence results also 
confirmed the improvement of TLR-4 surface expression in both cell lines 
(CFBE41o- and 16HBE14o-) (Fig. 8E). 
  
As we discussed earlier, TGF-β is responsible for the HIF-1α stabilization, this 
may explain our finding of increased TLR-4 protein and surface expression in the 
CF cells. Previous research was done by Kim et al. in macrophages showed that 
TLR-4 expression was up-regulated in hypoxia stress via hypoxia-inducible 
factor. In this study, they found small interfering RNA-mediated knockdown of 
HIF-1α expression repressed TLR-4 expression in macrophages, whereas over-
expression of HIF-1α lead to increase TLR-4 expression. Additionally, their 
chromatin immunoprecipitation assays revealed that under hypoxic conditions, 
HIF-1α binds to the TLR-4 promoter region [114]. 
 
Therefore, it can be speculated that exogenous TGF-β treatment enhances TLR-
4 expression via HIF-1α stabilization in CF cells. 
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4.6 Direct inhibition of ENaC up-regulate the ferroportin and TLR-4 
expression 
 
Recently, CF mice model with defective Cl− secretion resulted in an increase of 
Na+ and water absorption in lung epithelium, which is the consequence of 
overexpression of ENaC channel [141]. Deregulation of ENaC channels leads to 
depletion of airway surface liquid causing the thickening the mucus secretion, 
which reduce the mucociliary clearance of bacterial infections. 
 
ENaC channel play role in transportation of iron into the epithelial cells. Epithelial 
transport of iron into the cell seems to be associated with transcellular movement 
of sodium ions [105]. Overexpression of ENaC leads to not only increase 
Na+ intake in the cells but also increases the iron bypass in the cells [105]. In CF, 
an excess of Fe2+ suggests the interference with stability and activity of HIF-1α 
expression under hypoxia [107]. We hypothesize that blocking of ENaC might 
reduce the iron intake in the cells which reduce the increased iron concentration 
in the epithelial cells. Further, this might lead to HIF-1α stabilization due to 
reduced iron in the CF cells.  
 
In this study, we used EIPA (5-(N-Ethyl-N-isopropyl) amiloride) to inhibit ENaC 
channels. We observed the increase of ferroportin in CFBE41o- cells, which also 
might be the result of HIF-1α stabilization in cells. TLR-4 surface expression was 
found reduced in CF airways, which might compromise the innate immune 
responses. Less responsive CF airways during at the time of early bacterial 
infection might cause due to reduced TLR-4 surface expression. Consequently, 
this will delay neutrophil chemotaxis and migration across the epithelium and 
favor bacterial growth and biofilm formation [37]. So we examined the TLR-4 
expression upon ENaC channel inhibitor (EIPA) in CFBE41o- and 16HBE14o- 
cell lines. Although protein expression of TLR-4 did not show many differences 
upon increasing concentration of EIPA when compared to untreated cells. But 
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immunofluorescence experiments suggested an induction of TLR-4 surface 
expression upon EIPA treatments (Fig-10C). Further experiments of TLR-4-YFP 
plasmid transfection also confirmed that ENaC inhibition was linked with 
increased TLR-4 surface expression (Fig.10 1A). 
  
A possible explanation for the observed increased surface expression of TLR-4 
could be HIF-1α stabilization. As discussed earlier, blocking of ENaC might 
reduce the iron uptake in the epithelial cells [105], which can stabilize the HIF-1α 
in CF cells and associate with the TLR-4 up-regulation in CF cells. 
 
Not much study has been carried out in context with the ENaC and TLR-4 
regulation. Elucidating molecular pathways regarding direct inhibition of ENaC 
associated with improved TLR surface expression needs further investigation.  
 
Previously, it has been shown that epithelial sodium channel silencing facilitates 
restoration of the airway surface liquid level to allow usual mucociliary clearance 
[52]. Silencing ENaC using specific siRNAs can recover the surface hydration of 
CF and non-CF primary human bronchial epithelia (HBE) and can be one of the 
strategies to correct the airway surface fluid deficit in CF [142]. 
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5 Conclusion  
 
Based on the current study, the pathways by which TGF-β, ferroportin, and TLR-
4 linked to CF, are presented in the schematic diagram in Figure- 26. 
 
Reduced TGF-β and ferroportin expression might be a consequence of impaired 
HIF1α and could be restored by hypoxia/DFO mediated HIF1α stabilization. In 
addition, antagomirs miR-16 can be used to up-regulate the TGF-β. 
 
Thus, the current in vitro data gives us an idea that treatments such as 
exogenous TGF-β, EIPA (5-(N-Ethyl-N-isopropyl) amiloride) could be potentially 
successful in increasing ferroportin expression which might be an approach to 
overcoming the increasing iron load and improving the TLR-4 surface expression 
in CF.  
 
Further studies are necessary to elucidate downstream mechanism to reveal the 
increment of ferroportin and TLR-4 expressions in CF. Further confirmation in the 
primary airway epithelial cells from CFTR knockout mice or nasal epithelial cells 
obtained from patients with CF will support our findings and revealed the factors 
that play a role in the pathophysiology of CF.  
 
The potential clinical implications of the findings are profound because increased 
ferroportin expression will reduce iron concentration and maintain the iron 
homeostasis in CF airways. Further restoring the TLR-4 surface expression can 
prevent the chronic colonization of gram-negative bacteria such as 
Pseudomonas aerugionsa.  
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Figure 26: Schematic representation of pathways involved in TLR-4 and ferroportin 
expression in CF. Upregulation or downregulation of the respective targets is indicated 
with block arrows.
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7 Abbreviation 
 
16 HBE14o-cells Human bronchial epithelial cells  
AEC  Alveolar epithelial cell 
AM Alveolar macrophages  
AP  Alkaline phosphatase 
APCs,  Antigen-presenting cells 
APS Ammonium persulfate 
ASL Airways surface liquid 
ATP Adenosine triphosphate 
BAL Bronchoalveolar lavage 
BMP  Bone morphogenetic protein 
BSA Bovine serum albumin 
cDNA Complementary deoxyribonucleic acid 
CF Cystic fibrosis 
CFBE41o- Cystic fibrosis bronchial epithelial cells 
CFTR Cystic fibrosis transmembrane conductance regulator 
COPD Chronic obstructive pulmonary disease 
Ct  Threshold cycle 
Da Dalton 
DAMPs Danger- associated molecular patterns 
DAPI  4’,6-diamidino-2-phenylindole 
DCs Dendritic cells 
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DFO Deferoxamine 
DMT1 Divalent metal transporter 1 
EDTA  Ethylenediaminetetraacetic acid 
EIPA  (5-(N-Ethyl-N-isopropyl)amiloride) 
ELISA  Enzyme-linked immunosorbent assay 
EMT  Epithelial - mesenchymal transition 
ENaC Epithelial sodium channel 
ER stress Endoplasmic reticulum stress 
FPN Ferroportin 
gms Grams 
HCP1 Heme carrier protein 1 
HIF Hypoxia-inducible factor 
HIF1α Hypoxia-inducible factor-1α 
HJV Hemojuvelin 
HO-1 Hemeoxygenase-1 
HRP Horseradish peroxidase 
i-SMADs Inhibitory SMADs 
IFN-γ  Interferon-γ 
IL Interleukin 
IP-10 Interferon-γ inducible protein – 10 
IPF Idiopathic pulmonary fibrosis 
IRE Iron-responsive element 
Kb Kilobase pairs 
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KCl Potassium chloride 
kDa  Kilodalton 
KH2PO4 Monopotassium phosphate 
LPS Lipopolysaccharide 
LTGF-β  Latent precursor molecules of TGF- β 
M Molar (mole/litre) 
MCC Mucociliary clearance 
mg  Milligram 
min Minute(s) 
miRNA MicroRNA 
mL Milliliter 
mM Millimolar 
MMP Matrix metalloproteinase 
MUC5B Mucin 5B 
NaCl sodium chloride 
NADPH nicotinamide adenine dinucleotide phosphate-oxidase 
nm Nanometer 
nM  Nanomolar 
NO  Nitric oxide 
PAMPs Pathogen-associated molecular patterns 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
PFA  Paraformaldehyde 
 
112 
 
ABBREVIATION 
 
  
PHDs Prolyl hydroxylases 
PPRs Pattern recognition receptors 
q-PCR  Quantitive real-time- polymerase chain reaction 
RISC RNA-induced silencing complex 
ROS Reactive oxygen species 
RPM  Revolution per minute 
RT  Room temperature 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
TBST Tris-buffered saline and Tween 20 
TEMED  Tetramethylethylenediamine 
Tf Protein transferrin 
TGF-β receptor  Transforming growth factor receptor 
TLR Toll-Like receptors 
UPR  Unfolded protein response 
V Volt 
α-SMA Alpha smooth muscle actin 
μg  Microgram 
µL  Microliter 
μm  Micrometer 
μM  Micromolar 
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